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ABSTRACT 
 
Asthma is an inflammatory chronic disorder of airways of lungs.  In world, 
asthma is recognized as one of the most chronic diseases, which affects above 300 
million people all round the world.  In Pakistan, approximately 5-8% of adults are 
suffering from asthma.  Both environmental and genetic factors contribute towards 
the development of disease.  It is a multigenic disorder, and is due to different 
genetic factors, which also determine immune responses.  The purpose of the 
present study is to identify and investigate polymorphisms in major asthma genes.  
In present study, 34 SNPs of 28 genes were genotyped by iPLEX and Taqman 
assay.  HLA class II association was done by sequence specific PCR.  It is found 
that the minor alleles of IL10 (rs1800896) and IL13 (rs1800925) are related to 
increased asthma risk in our population.  It is also seen that the minor alleles of 
ADAM33 (rs2280091) are showing significant association with protection in 
Pakistani asthmatic population.  ADAM33 minor allele is having protective effect 
in females.  ACE homozygous insertion is reported to be associated with asthma 
risk in Pakistani population.  HLA class II DRB1*07 and DQB1*03 are found to be 
important in asthma pathogenesis and DQB1*06 is showing statistically signiﬁcant 
association with protection against the disease. 
 1 
Chapter 1 
INTRODUCTION 
 
Asthma is an inflammatory chronic disorder of airways of lungs.  Many cells 
and mediators involved in asthma pathogenesis are eosinophils, mast cells and T-
lymphocytes.  Asthma could be environmentally triggered and or genetically 
inherited (Martinez 2007).  Chronic inflammation is connected with bronchial 
hyperesponsivness and leads to episodes of wheezing, coughing, tightness in the 
chest, breathlessness, shortage of breath especially at night and in the morning.  
This episode is usually connected with variable obstruction, which is reversible 
spontaneously or by treatment.   
 
Asthma is recognized as one of the most chronic diseases, which affect more 
than 300 million people all around the world and annually causing approximately 
255,000 premature deaths (accounting for about one out of 250 deaths).  It has been 
described that if necessary action is not taken, asthma deaths would increase by 
almost 20% in the coming ten years.  In almost all countries, asthma occurs with 
variations in the level of development, but more than 80% deaths due to asthma 
occur in low and middle-income countries (Masoli et al., 2004).  In Pakistan, there 
is a day-by-day increase in asthma prevalence with an estimated 5% increase 
annually, out of which children between the age of 13 and 15 years are 20%.  
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Approximately 5-8% of adult Pakistani population is already suffering from 
the disease.  Recent data compiled about the prevalence of asthma in Pakistan 
shows 19 per cent prevalence in children and five per cent in adults (Pak.  Press 
Release, Feb 21
st
, 2009). 
 
Asthma is the disease that is associated with allergy -atopic disease, in which 
deviation of the immune system is the reason due to which an inflammation of the 
airways of lungs occurs that is non infectious.  Both environmental and genetic 
factors contribute towards the development of disease.  Asthma is a multigenic 
disorder, and its development is due to different genetic factors, which also 
determine immune responses (Martinez 2007).   
 
Asthma could run strongly in families and not only environment along with 
genetic factors interact in the asthma development but gene to gene interactions are 
also a major contributor.  Immune system linked genes e.g., human leukocyte 
antigen (HLA) class II genes, cytokines, β-adrenergic receptor gene, angiotensin 
converting enzyme (ACE) are reported in asthma pathogenesis (Malerba and 
Pignatti, 2005).  Highly polymorphic HLA class II genes, especially HLA-DQ 
genes, involved in antigenic presentation and T-cell restriction have been thought 
to be candidate loci for the etiology of asthma.   
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Different cytokines have also been associated with asthma.  The pathway of 
Interleukin 4/ interleukin 13 is one of the most important signaling pathways in 
atopy.  This has long been known from immunology that the important cytokine 
IL-4 is involved in immunoglobulin E (IgE) switching in B-cells.  In all atopic 
diseases, this common consequence is found.  In recent studies, it is reported that 
IL-13 is also a good mediator for immune responses in atopic diseases for the 
asthma induction as compared to IL-4.  The T regulatory cell produces both of 
these interleukins – IL-4 and IL-13.  A common pathway having a shared receptor 
chain (IL4Ra) and an intracellular transducer for signal (STAT6) is involved in 
signaling of both cytokines (Ober and Hoffjan, 2006).  In a meta-analysis study, 
IL4RA polymorphisms were reported in atopic asthma association (Nie et al, 2013). 
 
Two genes IL33 and IL-1 receptor-like 1 (IL1RL1) act in single signal 
transduction pathway.  The cytokine released on damaging of cells is encoded by 
IL33, however part of the IL-33 receptor complex is encoded by IL1RL1.  Asthma 
is associated with genetic variation at the IL33 and IL1RL1 loci, which can be 
dissected into independent signals with distinct functional consequences central for 
pathway to pathogenesis of asthma (Grotenboer et al., 2013).  In immune tolerance, 
IL-10 has an important role.  An increased asthma risk and Th2-type immunology 
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has been associated with lower production of IL-10.  IL-10 was associated with 
childhood asthma in other world populations (Koponen et al., 2013). 
 
The expression of IL-18 is very strong in the lungs in the fatal asthma group.  
In severe asthma patient’s treatment, the IL-18 signal transduction pathway may be 
of clinical benefit (Oda et al., 2014).  It has been concluded based on meta-analysis 
of results that IL-4RA Q576R polymorphism is significantly important for asthma 
risk (Xue et al., 2010).  In pathogenesis of atopic diseases including bronchial 
asthma, the involvement of FcεRI in the allergen-induced immune response is 
reported.  FcεRI consists of 3 subunits, namely, α, ß, and γ chains.  The β chain 
plays an important role in IgE-mediated allergic reactions (Akizawa et al., 2003).  
In some of the studies, the association of FCER1B gene has been reported 
(Shirakawa et al., 1996; Cui et al., 2003; Dmitrieva-Zdorova et al., 2012). 
 
In addition to cytokines, some chemokines (a family of small,8 – 14 kDa 
secreted proteins whose major function is to guide the migration and development 
of leukocytes) have also been found playing some major role in inflammation 
(Charo and Ransohoff, 2006, Rot and Andrian, 2004).  Due to their involvement in 
immune cell trafficking, chemokines have been implicated in a variety of 
inflammatory diseases, including rheumatoid arthritis, heart disease, asthma, type II 
diabetes and cancer (Acker et al., 1996; Pickup 2004). 
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Besides cytokines, genetic variations in different loci and genes have also 
been reported.  One such variation is at 17q21 locus, which is strongly associated 
with childhood nonallergic asthma.  Expression of the 17q21 genes, orosomucoid 
(yeast) like protein isoform 3 (ORMDL3) and gasdermin B (GSMDB), is affected 
by different disease-associated variants (Ono et al., 2014).  ORMDL3 has been 
identified as a candidate gene for susceptibility to asthma and its mechanisms by 
which it contributes to asthma pathogenesis is also reported in the context of 
allergic inflammation (Ha et al., 2013).  Some of the SNPs of ORMDL3 have 
shown associations with asthma in several populations (Balantic et al., 2013). 
 
Two distinct genes NOS1 and NOS3 are present on chromosome 12 and 7 
respectively.  Human airway epithelial cells express these two NOS isoforms 
(Asano et al., 1994).  It is reported that NOS1 and NOS3 control levels of NO to 
perform physiological functions properly (Bouzigon et al., 2012).  The 
Neuropeptide S Receptor (NPSR1) gene on chromosome 7 has been associated to 
asthma in several populations (Castro-Giner et al., 2010; Deley et al., 2009).  In 
some of the recent studies, NPSR1 genotypes are also positively affecting the 
allergic diseases (Kauppi et al., 2014). 
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Transcriptional activity in the TBXA2R gene was also influenced and 
identified in some genetic variants related to asthma phenotypes.  In asthmatic 
cases thromboxane pathways have important roles in airway inflammation and 
remodelling (Takeuchi et al., 2013).  In several genetic studies gene involved in 
chronic airway inflammation, the gene coding thromboxane A2 receptor has been 
reported to be associated with asthma (Kavalar et al., 2012).  Transforming growth 
factor-β1 (TGF-β1) is one of several candidate loci for the pathogenesis of asthma, 
and is highly polymorphic (Che et al., 2014).  Similarly, airway inflammation and 
immune response, both characteristics seen in asthma are affected by tumor 
necrosis factor alpha (TNF ) (Witte et al., 2002).  TNF  levels may have impact 
from genetic factors, and some of the TNF gene polymorphisms, present on 
chromosome 6p21, have been found associated with TNF  production and 
potential increased risk of asthma.  The TNF-alpha variant G-308A is studied in 
different populations and reported its association with asthma. 
 
A member of the ADAM (a disintegrin and metalloprotease domain) family 
is ADAM 33.  It is implicated in asthma and bronchial hyperresponsiveness and is 
a type I transmembrane protein.  Its locus on chromosome 20p13 is identified on 
genome-wide screen of 460 Caucasian families.  Its strong association with asthma 
was reported in world populations as ADAM33 is expressed in lung (bronchial 
smooth muscle and fibroblasts) and lymph nodes.  ADAM33 is an excellent 
candidate gene for asthma susceptibility (Bouzigon et al., 2008).  Polymorphisms 
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in β-adrenergic receptor and ACE genes may also predict the response to asthma 
therapy.  The ACE genes have been found important in pathogenesis of asthma.  A 
variant of ACE is insertion/deletion (I/D) polymorphism, which is found in 
different populations (Eryüksel et al., 2009).  An important factor studied in 
asthma-related research is the beta-2-adrenergic receptor, which is encoded by the 
ADRB2 gene (Thakkinstian et al., 2006).  The ADRB2 gene is a small gene on 
chromosome 5q31-q32 (www.ncbi.nlm.nih.gov), a region genetically linked to 
asthma (Hawkins et al., 2008).  An interesting positive association between the 
responsiveness of asthmatic patients to β-adrenergic agonists and common 
arginine-16 variants in the β-adrenergic receptor gene is also reported (de Paiva et 
al., 2014).  Toll like receptor 4(TLR4) is also reported to be associated with allergic 
diseases (Ullah et al., 2014). 
 
There is much importance of IL-4 and IL-13 pathway in the IgE secretion 
regulation.  Alterations in any main part of the described pathway can increase the 
risk of asthma development (Karp and Ewart, 2004).  Different genes have been 
identified associated with asthma in worldwide genetic studies.  Disease associated 
genotypes are taken as the same terms as other epidemiological risk factors which 
may be the predictor of disease and the size and relevance of effects of these 
genotypes can be judged objectively.  Genes involved in asthma in Pakistani 
population have not been studied yet so is disease severity with different 
8 
 
environmental risk factors.  It is hypothesized that Pakistani population might have 
different genetic make up from other world, which leads to asthma development.  
Therefore, the purpose of present study is to genotype Pakistani population for 
major asthma related genes under following objectives; 
o Identification of asthma susceptibility genes in Pakistani population 
o Investigation of polymorphisms in major asthma genes with asthma in 
Pakistani population  
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Chapter 2 
REVIEW OF LITERATURE 
 
Asthma is a respiratory disorder in humans, which is complex, and affects the 
airways that deliver air to the lungs.  Its association is with narrowness of airways 
and leads to periodic attacks of wheezing, chest congestion, cough, and other 
similar symptoms resulting in difficulty in breathing.  The immune system is 
triggered by asthma attacks leading to the elevated serum IgE levels.  Along with 
various environmental factors, different genes are reported to be associated with an 
individual’s ethnicity, susceptibility and asthma disease prevalence pattern.  For the 
screening of individuals at risk, the identified genes and their associated variants are 
of considerable use.  A number of genes and associated variants are reported to be 
linked strongly with increased asthma susceptibility in different ethnic groups all 
around the world.  These genes are not screened in Pakistani population. 
 
2.1 ASTHMA PREVALENCE 
 
Regardless of the world development, asthma is rapidly increasing over the 
last 20 years all over the world.  Approximately more than 5 million people in UK 
receive treatment for asthma, among them children are about 1 million and adults 
are more than 4 million.  Bad management of asthma results in increased incidence 
of asthma and hospitalization of the patients due o asthma (Kaufman, 2011).  In the 
10 
 
whole world, approximately 300 million people are suffering from asthma and there 
is a day by day increase in number of affected individuals.  The asthma prevalence 
in our Pakistani population is increasing at the rate of 5% per year; among them 
children between 13 to 15 years of age are 20% to 30%.  About 12% of the total 
Pakistani population, which is approximately 20 million, is affected with asthma 
(Pak, Press Release, May 2011).  Since last two decades, there are marked 
established international guidelines for asthma treatment and management, still to 
cure the disease completely is a challenge.  Even in developed countries such as UK 
there is high death rate that is three persons per day due to asthma, (Kaufman, 
2011). 
 
2.2 ASTHMA TYPES 
 
Asthma is also sometimes known as bronchial asthma because the narrowing 
of the bronchial airways of lungs is involved in it.  Asthma can be grouped as atopic 
which starts in childhood and is associated with risk factors which are identifiable 
and has genetic predisposition.  Mostly asthma has an association with family 
history of allergic diseases.  Allergic asthma is the one, which is increased by 
allergens, such as dander of pet, pollen, and preservatives of food or some fungus.  
Allergic asthma looks as seasonal because it is often due to allergies that are mostly 
seasonal.  During asthma attack excessive IgE antibodies are produced from B 
lymphocytes which bind to inflammatory cells and result in narrowing of airways of 
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lungs making the breathe difficult.  Every asthmatic case is not due to atopy.  The 
patients who develop asthma at adult age may have viral respiratory infections as a 
secondary response and it is termed as non-atopic type of asthma.  In this type of 
asthma immunoglobulin E (IgE) is not released and some other triggers are 
involved (Ward et al., 2010). 
 
2.3 ASTHMA PATHOPHYSIOLOGY  
 
Asthma is triggered by various environmental allergens that lead to elevation 
of immune system.  Different works have reported these environmental allergens, 
which include proteases, dust mites, pollens and animal dander.  In the disease state 
an elevated expression of different cell types in bronchial mucosa such as, 
eosinophils, mast cells, macrophage, lymphocytes and basophils is seen.  With these 
cells other inflammatory cells are involved in the airway inflammation which leads 
to the airways hyper responsiveness, limitation in airflow, symptoms of respiration, 
and chronic disease.  Along with respiratory track cells, these cells bring about the 
changes in the structure of airways and increase resistance in airflow.  Hereditary 
factors causing asthma are mostly affected by factors of environment.  Various 
studies recommend that tissues microenvironment play a vital and major role at 
start, complexity and progression of asthma (Amrendra Kumar and Balaram Ghosh, 
2009). 
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2.3.1 Effect on Lungs Airways 
 
Inflammation in the walls of the airways during an asthma attack leads to 
swelling along with fluid accumulation in the walls covering the mucous 
membrane with fluid.  The remaining space in the airways is filled by sticky mucus 
making it difficult to breathe.  Because free movement of flow of air inside and 
outside of the lungs is not possible, a wheezing or whistling sound may be 
produced.  During most damaging attacks there is no wheezing, the reason is that 
the amount of air that moves in to the air ways is too small to make such sound.  
These changes stimulate sensory nerves in the airways (Kaufman, 2011).  
Additionally when the surrounding muscles of the lungs tighten or go into spasm, 
the airways of the lungs may become blocked or obstructed.  This retards air to 
move freely inside the lungs or the airways of the lungs may be clogged due to the 
mucus, resulting in difficulty to breathe. 
 
Attacks of asthma may be mild, moderate, or harsh, and can last for a few 
seconds, minutes, hours, or few days.  They can have occurrence anytime at any 
place.  Mostly it occurs at the time of night.  Sometimes, the signs and symptoms 
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are shown before an attack is going to occur, but sometimes there are no signs and 
symptoms before the attack. 
 
2.3.2 Remodeling of Airways 
 
Irreversible structural modifications in airways are often seen in chronic 
asthma due to abnormal remodeling and repair processes.  Remodeling of airway is 
associated with epithelial damage, increased matrix deposition and smooth muscle 
hyperplasia.  These changes in structure are mainly associated with the symptoms of 
asthma (Kedda et al., 2006). 
 
2.4 ASTHMA RISK AND TRIGGER FACTORS 
 
 As asthma is an interactive disease, the risk factors of asthma can be 
classified as environmental and genetic factors. 
2.4.1 Environmental Factors 
 
Many environmental risk factors are involved in asthma due to reason that the 
expression of disease susceptibility genesis increased.  Allergens which are indoor 
such as fungus, cockroaches mites, dust in house, hair of animals are the 
environmental risk factors mainly associated with asthma.  Allergens outside the 
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house include pollution in air, pollen, certain food items, active and passive smoke 
and clothing’s.  Certain drugs, obesity, infections in respiratory tract and parasitic 
viral or bacterial infections, for example, Chlamydia, M.  pneumonia and mold are 
also included in risk factors.  Inhalation of heavy smoke, ozone and endotoxin, as 
well as gastroesophageal backflow and emotional changes also induce nonallergic 
asthma (Abdulbari et al., 2005).  The severity of asthma attack is also affected by 
seasonal fluctuations.  Smoking habits of mothers during pregnancy and 
atmospheric pollution can also result in elevated levels of IgE and asthma 
development and airway hyper responsivenessof lungs (Ward et al., 2010). 
 
2.4.2 Genetic Factors 
 
The genetic factors include different genes present in the host that could be 
associated to different allergens somehow.  The genetic factors contribute up to 
79% alone (Holgate et al., 2006).The literature emerging picture suggests asthma or 
asthma related phenotypes are associated with hundreds of genes as shown in figure 
1 (Ober and Hoffjan, 2006; Zhang et al., 2009).  Currently major efforts are 
underway, taking use of new techniques such as genome-wide association studies of 
single-nucleotide-polymorphisms (SNP), to see importance of these genes in larger 
populations and also to identify novel and new genes (Moffatt et al.,2007; Ober et 
al., 2008; Weidinger et al., 2008). 
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More than 100 genes have been seen to be associated with asthma in at least 
one study regarding genetic association.  However, these types of studies need to be 
replicated to ensure that the results are accurate.  Towards the start of 2006, about 
25 genes have been found to be associated with asthma in six or more different 
ethnic populations. 
 
In at least 1,000 published papers, SNPs in genes that are candidates for 
asthma and allergy were examined.  Although most of these genes have not been 
replicated, this is required to check whether these finding are true observations 
(Figure 2).  The genes that are reported in many studies includ ADAM33, 
FCER1B,ADRB2, IL4, CD14, HLA-DRB1, HLA-DQB1, TNF, IL4RA, and IL13 
(Postma et al., 2011).  Immune system linked genes e.g., human leukocyte antigen 
(HLA) class II genes, cytokines, β-adrenergic receptor gene, angiotensin converting 
enzyme (ACE) are reported in asthma pathogenesis.  Highly polymorphic HLA 
class II genes, especially HLA-DQ genes, involved in antigenic presentation and T-
cell restriction have been thought to be candidate loci for the etiology of asthma 
(Malerba and Pignatti, 2005). 
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Figure 1: Hypothetical scheme of asthma pathogenesis. (Karp and Ewart, 2004).  
 
Different cells are shown to be effected by various genes and then resulting in 
asthmatic pathogenesis  
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Figure 2: Susceptibility genes for asthma (Donata Vercelli 2008). 
Pollens and allergens are effecting on dendritic cells and resulting in 
inflammation. This inflammation is effecting different group of genes at 
different levels and resulting in asthma pathogenesis. 
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In the present study, different genes and polymorphisms which have been 
found to be strongly associated with asthma in other populations were selected and 
from these the SNPs which have been reported in maximum studies were analyzed.  
The genes that were selected for analysis in the present study are described on the 
following pages. 
 
2.5 HUMAN LEUKOCYTE ANTIGENS (HLA) 
 
In humans, the major histocompatibility complex (MHC) is known as human 
leukocyte antigen (HLA) system.  Multiple numbers of genes are present in this 
super locus which has relationship with function of immune system in humans.  
This is the gene group localized on chromosome 6, which encodes proteins 
presented on cell-surface antigens and several other genes.   
 
The antigens of HLA class II (DM, DP, DOA, DOB, DQ, & DR) present 
antigens to T-lymphocytes from the outer side of cell.  Multiplication of these T-
helper cells is stimulated due to these specific antigens, and these T-helper cells 
stimulate antibody-producing B-cells to make antibodies in response to that specific 
antigen.  Suppressor T-cells suppress these self-antigens.  List of alleles of HLA 
DRB and DQB are shown in table 1. 
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Figure 3: Simplified map of the HLA region on chromosome 6 (Westover et 
al., 2011). 
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Table 1: HLA DRB and DQB alleles Genotyped in Asthma Patients 
HLA-DRB1*(15) HLA-DQB1 (11) 
*0101-04 *0201-02 
*0301-05 *0301/04 
*0401-22 *0302 
*0701 *03032 
*0801-11 *0305 
*0901 *0401-02 
*1001 *0501-04 
*1101-22 *0601 
*1201-03 *0602 
*1301-22 *0603 
*1302 *0604-09 
*1401-22   
*1501-05   
*1601-02   
*1701   
 
 
 
21 
 
 
Association of DQB1*0503 and the allelic combination DQB1*0201/0301 
was found with susceptibility of asthma.  Conversely, allele DQB1*0501 and one 
haplotype DQA1*0101-DQB1*0501-DR1 reported significant protection as found 
in healthy control subjects in French population (Bignon et al., 1994).  HLA 
DRB1*are found highly associated in an English population study (Moffatt et al., 
1999). 
 
2.6 HUMAN LEUKOCYTE ANTIGEN G (HLA-G) 
 
HLA-G is part of the HLA class I paralogues that are heavy chained.  This is a 
heterodimer molecule of class I containing a light chain and a heavy chain (beta-2 
microglobulin).  It is involved in presenting the foreign antigens to the immune 
system.  In asthmatics, it is upregulated on the bronchial epithelium.  It is reported 
that susceptibility to asthma has been influenced by genetic polymorphism 
affecting expression of HLA-G (Le Page et al., 2013). 
 
2.7 TUMOR NECROSIS FACTOR ALPHA (TNF ) 
 
Tumor necrosis factor (TNF) alpha affects airway inflammation and immune 
response, which are characteristics found in asthma.  TNF gene maps within cluster 
on MHC class III region, which clusters on chromosome 6p21.  Genetic factors may 
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influence, and different polymorphisms in the TNF gene are associated with TNF  
production and TNF  levels may be affected by genetic factors, which result in 
potential increased risk of asthma.  The association of a G-308A variant of TNF-
alpha with asthma is found in different populations (Witte et al., 2002) 
 
2.8 CYTOKINES 
 
Different cytokines have also been associated with asthma.  The interleukin 4 
/ interleukin 13 pathway is one of the most intriguing signaling pathways in atopy.  
In immunological studies, this has been understood that IL-4 is one of the cytokine 
mainly involved in immunoglobulin E (IgE) switching in B-cells, animportant 
feature commonly found in all diseases related to atopy.  Presently it has been 
found that as compared to IL-4, IL-13 is the highly potent mediator of atopic 
immune responses in the asthma induction.  The central cell related to atopy, the T 
regulatory cell, produces two cytokines IL-4 and IL-13.  These two cytokines signal 
in a same pathway containing sharing between receptor chain (IL4Ra) and an 
intracellular signal transducer (STAT6) (Ober and Hoffjan, 2006).   
 
Cytokines are mainly proteins signaling extracellular, usually the size is 
smaller than 80kD, and mostly are glycosylated.  These are produced by various 
types of cells, which are involved in interactions of one cell with other cell working 
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through some specific receptors on the target cells surface (Tomita et al., 2004).  
Following are the cytokines selected for the present study. 
 
2.8.1 Interleukin 10(IL10) 
 
Monocytes can produce IL-10 upon Programmed cell death protein 1 (PD-1) 
which is triggered in these cells (Said et al., 2010).  Cytotoxic T-cells release IL-10 
that retards the activity of Natural Killer cells during the response of immune 
system against any viral infection. 
 
Pro-inflammatory cytokines’ synthesis just as IL-2, IFN-γ, IL-3, TNFα and 
GM-CSF presented by cells for example macrophages and regulatory T-cells can be 
inhibited by IL-10.  The capacity of antigen presenting cells to present antigens is 
suppressed by IL-10; however, it also causes stimulation of certain mast cells and T 
cells and resultantly stimulates antibody production and B cell maturation. 
 
The effect of functional polymorphisms of IL10 on allergy and asthma 
exacerbations is modified by dust mite exposure.  Three SNPs in IL10 (rs1800896, 
rs3024492, and rs3024496) were found associated with dust mite allergy.  The rare 
allele homozygosity of any of the 3 SNPs was seen associated with more risk of 
disease (Hunninghake et al., 2008). 
 
24 
 
2.8.2 Interleukin 1 receptor, type I (IL1R1) 
 
It is a key mediator which is involved in most of the cytokine-induced 
inflammatory and immune system responses.  It is the gene, which is localized in a 
cluster of related cytokine receptor genes on chromosome 2q12.  Part of the IL-33 
receptor complex is encoded by IL1RL1.  Asthma associated genetic variations at 
the IL33 and IL1RL1 loci can be dissected into independent signals with different 
functional consequences for this pathway, which is basic to pathogenesis of asthma 
(Grotenboer et al., 2013). 
 
2.8.3 Interleukin 13 (IL13) 
 
A class of protein-degrading enzymes is induced by IL-13, also called matrix 
metalloproteinases (MMPs), in lungs airways.  These are the enzymes that are 
needed for induction of egression of effete parenchymal inflammatory cells into the 
airway lumen from where they are cleared afterwards.  Along with several different 
agents, these are the MMPs, which are induced by IL-13 as portion of the 
mechanism that give protection against more inflammation due to allergy, which 
predisposes to asphyxiation.  IL13 is a 2.9 kb gene characterized by extensive 
linkage disequilibrium, therefore genotyping some of the polymorphisms gave 
enough genetic associations assessment.  This cytokine is reported to be important 
for the allergen-induced asthma pathogenesis but operates through some of the 
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mechanisms that are independent of eosinophils and IgE.  Chronic obstructive 
pulmonary disease (COPD) and asthma are chronic diseases of respiratory system 
that involve an interaction between environmental and genetic factors.  It is 
suggested that IL13 has a critical role in pathogenesis of both of these diseases.  IL-
13 is seen to be primarily associated with the induction of disease of airways; it also 
has anti-inflammatory properties.  Three of the IL13 SNPs rs1881457, 
rs1800925and rs20541 were reported to be associated with the risk of atopy 
(Bottema et al., 2010).  The SNPs rs1295685 and rs20541 were significantly 
associated with increased IgE levels in pooled analyses of different populations. 
 
2.8.4 Interleukin 33 (IL33) 
 
IL-33 receptor was first discovered as a molecule which is like IL-1 receptor 
(Tominaga, 1989).  This was found to be expressed preferentially in Th2 cells and 
started to attract many researchers working on allergy (Yanagisawa et al., 1997). 
 
2.8.5 Interleukin-18 (IL18) 
 
IL-18 is the cytokine which is part of the superfamily of IL-1 and is originated 
from macrophages and different other cells.  By binding to the interleukin-18 
receptor the work of IL-18 starts, and along with IL-12 it promotes cell-mediated 
immunity following microbial products infection just as lipopolysaccharide (LPS).  
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IL-18 is well known to initiate severe inflammatory reactions, which leads to the 
suggestion that it has very important role in many of the inflammatory disorders.  
IL-18, marked as an IFN-γ–producing factor, is a proinflammatory cytokine that has 
a key role in activation of TH1 cells.  IL-18 may play a critical role to promote 
immunologic responses and may reflect activity of the disease in mild and moderate 
asthma attacks (Tanaka et al., 2001). 
 
2.8.6 Interleukin 4 Receptor alpha (IL4RA) 
 
IL-4, a pleiotropic cytokine is released by activated Th2 cells and mast cells, 
and plays a crucial role in immune system responses.  The IL-4 effects are enhanced 
after binding to high affinity receptor complexes found on hematopoietic as well as 
non-hematopoietic cells.  Hematopoietic responses to IL-4 are produced by a high 
affinity receptor complex comprised of the common cytokine γc chain (CD132) and 
the IL4Rα (CD124) subunit.  The IL4Rα subunit in combination with the IL13Rα 
chain serves as a functional complex for IL-13 in non-hematopoietic cells.  IL4Rα is 
a type I transmembrane protein consisting of ser/Pro-rich regions in cytoplasmic 
domain, same to those located in the GM-CSF receptor ß-chains and the IL-2 
receptor.  The gene IL4RA is localized at chromosome 16p (16p12.1) (Pritchard et 
al., 1991), a region previously described linked with atopy in several populations 
(Ober et al., 2000; Deichmann et al., 1998).  It is evident that association of IL4 
polymorphisms with total IgE levels and resultantly leading to different phenotypes 
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of allergy and asthma, along with its ethnical differences have also been seen 
(Basehore et al., 2004).  Specifically, asthma phenotype has been seen to be 
associated with the promoter region of IL4 (Rosenwasser and Borish, 1997) and in 
this region a polymorphism at 33C>T has been reported (Suzuki et al., 1999).  IL-4 
works with the help of IL-4 receptor (IL-4R) which has two subunits, an α chain 
(IL-4Rα) and a γ chain (γc) (Nelms et al., 1999; Miloux et al., 1997).  IL-4Rα is a 
constituent part of the IL-4 as well as the IL-13 receptor complexes (Mak and 
Simard, 1999). 
 
IL-4 and IL-13both are the genes, which on their receptors share a common 
IL-4Rα chain and code cytokines (immunoregulatory proteins) that share their 
functions.  By stimulating IgE synthesis, these cytokines play a central role in 
allergy (Akdis, 2006).  A statistically significant association rs1801275and allergic 
asthma was reported in a recent meta-analysis of seven studies (Lozaand Chang, 
2007). 
 
2.8.7 Thymic Stromal lymphopoietin (TSLP) 
 
In humans, the cytokine thymic stromal lymphopoietin (TSLP) is found to be 
related to inflammatory diseases due to allergy.  It has been confirmed that TSLP is 
an important initiator of allergic inflammatory diseases for example asthma and 
atopic dermatitis (Bird, 2005).  In many disease states it is reported that TSLP 
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expression is linked to asthma (Ying et al., 2005), atopic dermatitis (Ebner et al., 
2007), inflammatory arthritis (Koyama et al., 2007), and eczema and other allergic 
states (Soumelis and Liu, 2004; Soumelis et al., 2002).  A hemopoietic cytokine is 
encoded by the gene that is supposed to be presented by a receptor complex that is 
heterodimeric and is constituted of the receptor of thymic stromal lymphopoietin 
and the IL-7R alpha chain.  This primarily affects the cells of myeloid and starts the 
release of chemokines attracted by T cell from monocytes, and promotes the 
dendritic cells CD11c (+) maturation step.  The product in form of protein enhances 
response of T helper type 2 (TH2) cells which have association with immune 
system in different inflammatory diseases, including inflammation due to allergy, 
asthma, and chronic obstructive pulmonary disease.  A TSLP gene variant has 
association with asthma and airway hyperresponsiveness.  TSLP has an association 
with allergic rhinitis in asthmatic children.  In an analysis two SNPs in TSLP, 
rs2289276 and rs1837253 were significantly associated with a reduced chances of 
asthma (Hunninghake et al., 2010). 
 
2.9 CHEMOKINES 
 
Chemokines are a group of small cytokines, or signaling proteins secreted by 
cells.  Their name is derived from the ability of inducing direct chemotaxis in 
nearby responsive cells; they are chemotactic cytokines.  Following are the 
chemokines listed in which polymorphisms are selected for the present study. 
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2.9.1 Clara cell protein 16 (CC16) 
 
Asthma and related phenotypes are found to be linked to chromosome 11q12-
13 and this has been indicated in genome-wide searches and candidate gene studies 
(Cookson et al., 1989; Daniels et al., 1996).  Including some other important genes, 
the gene Clara cell protein 16 (CC16) has been identified in this region.  It 
represents various immunomodulatory and anti-inflammatory effects (Singh and 
Katyal, 1997).  The protein CC16 is mainly expressed in the lung and it is likely 
that its anti-inflammatory effects are to be most pronounced in the airways (Sengler 
et al., 2003). 
 
2.9.2 Chemokine (C-C motif) ligand 5 (CCL5) 
 
CCL5 is chemotactic for eosinophils, T cells and basophils, and plays a critical 
role in recruiting leukocytes into inflammatory places.  This chemokine in humans 
has been mapped to chromosome 17 (Donlon et al., 1990).  By the assistance of 
specific cytokines (i.e., IL -2 and IFN -γ) that are liberated by T cells, induction of 
CCL5 into the activation and proliferation of some of the natural-killer (NK) cells to 
make CHAK (CC-Chemokine-activated killer) cells (Maghazachi et al., 1996). 
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2.9.3 C-C motif chemokine 11 (CCL11) 
 
This gene is encoded on three exons and is located on chromosome 17 
(Kitaura et al., 1996; Hein et al., 1997).  The chemoattractant for eosinophils which 
is the most selective, Eotaxin (CCL11), assists peripheral blood eosinophils 
recruitment into the lung during severe inflammation due to allergy (Rothenberg, 
1999; Gonzalo et al., 1998).  CCL11 is localized at a region of chromosome 
17q21.1 which is mostly reported to have linkage to asthma in genome-wide linkage 
studies (Nickel et al., 1997; Koppelman et al., 2002, Barnes et al., 2001).  CCL11 
locus is a key marker to determine serum total IgE levels between asthmatic patients 
(Raby et al., 2006). 
 
2.10 BETA 2 ADRENERGIC RECEPTOR (ADRB2) 
 
The ADRB2 gene present on chromosome 5 is intron less.  Various 
polymorphisms, point mutations, and/or down regulation of this gene are associated 
with obesity, nocturnal asthma, and diabetes.  A study of Scottish asthma patients 
concluded that rs1042713 (A) alleles are significantly associated with asthma (Basu 
et al., 2009).  Polymorphisms in β-adrenergic receptor gene may also predict the 
response to asthma therapy.  It is very interesting that there is a positive association 
between the response shown by asthmatic patients to β-adrenergic agonists and the 
variants of arginine-16in the β-adrenergic receptor gene. 
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2.11 NITRIC OXIDE SYNTHETASE GENE(NOS) 
 
Nitric oxide (NO) production is regulated by the nitric oxide synthase 
pathway.  Synthesis of NO is from l-arginine by three NO synthase (NOS) isoforms.  
Different genes produce these NOS isoforms.  In humans, these have been 
characterized as: neuronal NOS (nNOS) encoded by the gene NOS1, inducible NOS 
(iNOS) encoded by the gene NOS2A, and endothelial NOS (eNOS) encoded by the 
gene NOS3.  The intracellular l-arginine availability is a factor that is rate-limiting 
in NO production (Morris, 2004).  These three isoforms of NOS are expressed in 
airway epithelium (Ricciardolo et al., 2006; Sheffield et al., 2006; Shimokawa and 
Tsutsui, 2010).  Epigenetic differences in NOS genes may alter NO synthesis by 
affecting NOS function or expression.  These changes, in turn, have major influence 
on the respiratory health outcomes.  The endogenous nitric oxide (NO) plays a 
critical role in regulating physiology of airway functions and is implicated in 
diseases of airways such as asthma (Ricciardolo et al., 2006; Ghoshand Erzurum, 
2011).  One of the SNP located in the NOS3 gene rs1799983 (also known as 
Glu298Asp, or G894T) was associated with pregnancy-induced hypertension in 
African women (Hillermann et al., 2005).   
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2.12 NEUROPEPTIDE S RECEPTOR 1 (NPSR1) 
 
NPSR1 was first specified as a gene susceptible for asthma by positional 
cloning (Laitinen et al., 2004).  The evidence of genetic association was supported 
by significance in single nucleotide polymorphism (SNP) and associations of 
haplotypes with asthma in three varying populations.  Recently, in seven 
independent populations , the association of NPSR1 to asthma and allergy has been 
replicated (Hersh et al., 2007; Feng et al., 2006; Melen et al., 2005; Kormann et al., 
2005; Daley et al., 2009; Castro-Giner et al., 2010;Malerba et al., 2007).  It has 
been reported in different studies that NPSR1 is involved in inflammatory diseases 
of skin and intestine (D'Amato et al., 2007; Sundman et al., 2009), traits related to 
neural system such as sleep and circadian phenotypes (Gottlieb et al., 2007) and 
anxiety (Leonard et al., 2008). 
 
2.13 TOLL LIKE RECEPTOR (TLR4) 
 
The Toll like receptor present on chromosome 9 plays a basic role in 
recognition of pathogens and innate immunity activation.  The TLR4 presents some 
polymorphisms implicated in increased susceptibility to various diseases such as 
atherosclerosis (Kiechl et al., 2003), asthma (Hold et al., 2007), malaria 
(Mockenhaupt et al., 2006), and also infection with the H.  pylori associated with 
gastric cancer and its precursors (Lorenz et al., 2001).  Two SNPs in 
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TLR4+896A/G (rs4986790) and +1196C/T (rs4986791) have received special 
attention in some studies, although the results are still controversial (Achyut et al., 
2007; Wu et al., 2006;Garza-Gonzalez et al., 2007). 
 
2.14 FC EPSILON RECEPTOR I BETA-CHAIN (FCER1B) 
 
FCER1B gene is located on chromosome 11.  An uncertain functional 
consequence of coding variants of this gene is associated with asthma.  A common 
promoter region polymorphism at the FCER1B− 109C/T was identified, although in 
whole of the coding region no variant was found.  This polymorphism in the 
promoter region is found to be associated with asthma (Hizawa et al., 2000). 
 
2.15 OROSOMUCOID (YEAST)-LIKE 3 (ORMDL3) 
 
It was demonstrated in a genome-wide association study (GWAS) of asthma 
that several genes on chromosome 17q21 (one of the marker is orosomucoid like 3; 
ORMDL3) were highly and reproducibly associated with asthma in three asthma 
cohorts of different populations (Moffatt et al., 2007).  The confirmation of 
ORMDL3 as an asthma-associated gene has been done in additional GWAS studies 
and in genetic association studies in diverse ethnic backgrounds communities 
(Bouzigon et al., 2008; Galanter et al., 2008; Moffatt et al., 2010).  Presently, the 
function of ORMDL3 in the asthma and in lung function is not known.  In 
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independent replication studies this 17q21 locus has shown high association with 
childhood asthma diagnosis in 3,301 cases from the English population and in 2,320 
cases from a cohort of children of German population.  These results describe that 
genetic variants regulating ORMDL3 expression are determinants of asthma 
susceptibility in children (Moffatt et al., 2007). 
Single-nucleotide polymorphism (SNP)-based genome-wide association study 
has shown that in Caucasians, genes located at chromosome 17q21 were found to be 
linked to asthma in childhood but not with atopy, with the highest association being 
shown for the SNP rs7216389 of the ORMDL3 gene.  In Chinese asthmatics this 
type of association was not reported.  This study showed the frequencies of 
genotype and allelotype of 10 SNPs at chromosome 17q21, and inquired the 
relationship between these SNPs and plasma IgE and asthma in southern Chinese 
children.  In this study 315 cases and 192 healthy controls were recruited.  In 
rs7216389, the allele frequency of C allele was varied significantly from 0.232 in 
controls, 0.389 in Han Chinese to 0.536 in Caucasians.  Diagnosis of asthma was 
associated with rs7216389, rs11650680, whereas rs11650680 was found to be 
associated with atopy (Leung et al., 2009). 
 
2.16 GASDERMIN A (GSDMA) 
 
GSDMA gene is located at chromosome 17q21.2.The region is thought to be 
associated with susceptibility to asthma and intermediate phenotypes of asthma, 
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such as increased IgE levels.  In Korean asthmatic children GSDMA polymorphisms 
had an active role in the development of childhood asthma (Yu et al., 2011). 
 
2.17 THROMBOXANE A2 RECEPTOR (TBXA2R) 
In a very detailed sequencing of the TBXA2R gene in Japanese population 
rs1131882 (c.795 T>C) has shown association with asthma and various phenotypes 
related to asthma (Takeuchi et al., 2013).  In a study on Korean cerebral infarction 
patients SNPs in the TBXA2Rgene rs3786989 (–3372G>C), rs11085026 
(+4710T>C) and +4839T>C were analyzed (Sun et al., 2009). 
 
2.18 TRANSFORMING GROWTH FACTOR BETA 1 (TGFΒ1) 
 
TGF-β1 located on chromosome 19, acts a keypart in monitoring the 
immunity, and shows various functions on different types of cell, or cells at varied 
stages of development.  Many of the leukocytes (or immune cells) release TGF-β1 
(Letterio and Roberts, 1998).  A SNP in the TGF β 1 gene’s promoter region, 
rs1800469, has been shown association with raised risk for chronic obstructive 
pulmonary disease (COPD).  Although smoking is the major risk factor, smokers 
with C allele for rs1800469 (or 2 other TGFB1 SNPs, rs1982073 and rs2241712) 
were reported to be more likely to develop COPD, based on a study of ~700 
Caucasians (Celedón et al., 2004). 
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2.19 ADISINTEGRIN AND METALLOPROTEINASE DOMAIN-33(ADAM 
33) 
 
A member of the ADAM (a disintegrin and metalloprotease domain) family 
is encoded as ADAM 33.  It is a transmembrane protein which is type I and is 
implicated in bronchial hyperresponsiveness and asthma.ADAM33 is mapped on 
chromosome 20p13.  It was first discovered by positional cloning in 2002 as 
susceptibility gene for asthma (Su et al., 2008).  Its strong association with asthma 
was reported in world populations as expression of ADAM33 is in lung (fibroblasts 
and bronchial smooth muscle) and lymph nodes.  ADAM33 is an excellent 
candidate gene for asthma susceptibility.  ADAM33are highly expressed in smooth 
muscle cells and airways fibroblast.  Any aberration in the action of ADAM33 leads 
to functional abnormalities of fibroblasts and smooth muscle cells of airways of 
lungs.  It is more strictly expressed in mesenchymal cells.  Association of ADAM33 
with hyper responsiveness in bronchial region and accelerated functional declineof 
lungs with time strongly recommends it is involved in the structural airway asthma 
components, for example remodeling (Holgate et al., 2006).  Early increased risk of 
asthma due to SNPs reported at chromosome 17q21 and risk increases due to 
environmental tobacco smoking (Bouzigon et al., 2008). 
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2.20 ANGIOTENSIN-CONVERTING ENZYME (ACE)  
 
The gene ACE encodes two isozymes.  Expression of the somatic isozyme is 
high in different tissues, primarily in the lung, including vascular endothelial cells, 
testicular Leydig cells and epithelial kidney cells, whereas the germinal isozyme 
expression is mainly in sperm.  ACE gene is an I/D polymorphism in intron 16 of 
the gene meaning that the presence (I) or absence (D) the carriers of the ACE 
insertion allele of a repeat of alu (Wang et al., 2008).  Polymorphisms in ACE gene 
may also predict the response to asthma therapy.  An insertion/deletion (I/D) variant 
of ACE is found in different populations.  (Eryüksel et al., 2009). 
 
About 153 SNPs reported in IL4 and some of these are associated with 
asthma (Noguchi et al., 1998).  There are 96 SNPs in IL13 and 90 in ADRB2 
reported, some have associations with asthma in other world population (Hawkins 
et al., 2006).  Case - control and familial genetic association studies have mainly 
shown a link between asthma and ADAM33.  The association of ADAM33 with 
hyperresponsiveness in bronchial tract and accelerated lessening in function of lung 
over time points strongly to the involvement of this gene in the asthma.  About 211 
SNPs have been reported in ADAM 33 till date.  Few of them have strong 
association with asthma (Su et al., 2008). In the present study different genes and 
their SNPs were selected. The purpose is to genotype Pakistani population for 
major asthma related genes to identify asthma susceptible genes and SNPs.
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Table 2: Single Nucleotide Polymorphisms (SNPs) selected for 
Genotyping in Asthma Patients. 
Gene Chr 
location 
rs # Allele 
(minor/major) 
IL10 1 rs1800871 T/C 
IL10 1 rs1800896 G/A 
IL1R1 2 rs10173081 T/C 
ADRB2 5 rs1042713 A/G 
IL13 5 rs1295685 T/C 
IL13 5 rs1800925 T/C 
TSLP 5 rs1837253 T/C 
IL13 5 rs20541 T/C 
TSLP 5 rs2289278 G/C 
HLA-G 6 rs1063320 C/G 
NOS3 7 rs1799983 T/G 
NOS3 7 rs1800779 G/A 
NPSR1 7 rs740347 C/G 
IL33 9 rs1342326 G/T 
TLR4 9 rs4986790 G/A 
IL18 11 rs1946518 T/G 
FCER1B 11 rs2583476 C/T 
CC16 11 rs3741240 A/G 
NOS1 12 rs2682826 T/C 
IL4RA 16 rs1801275 G/A 
IL4RA 16 rs1805011 C/A 
ORMDL3 17 rs11650680 T/C 
CCL11 17 rs17809012 G/A 
CCL5 17 rs1800825 C/T 
GSDMA 17 rs3894194 T/C 
ORMDL3 17 rs7216389 C/T 
ORMDL3 17 rs8079416 T/C 
TBXA2R 19 rs1131882 A/G 
TFGB1 19 rs1800469 T/C 
TBXA2R 19 rs4523 C/T 
ADAM33 20 rs2280091 G/A 
ADAM33 20 rs528557 G/C 
ADAM33 20 rs543749 T/G 
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Chapter 3 
MATERIALS AND METHODS 
 
This study is a case control population based study.  Ethical clearance was 
received by the ethical committee of the parent organization (ERC-08-01) and from 
the Ethical Committee for the Use of Human Subjects, Pir Mehr Ali Shah Arid 
Agriculture University Rawalpindi.  Written consent from each participant was 
obtained before taking the samples. 
 
3.1 BLOOD SAMPLE COLLECTION FOR THE PURPOSE OF 
RESEARCH 
 
 Total 854 blood samples including 333 asthma cases and 521 normal healthy 
controls were recruited for the present study.  Cases of asthma were selected for sample 
collection from the outpatient clinics of Rawalpindi, Islamabad and Lahore.  Chest 
specialists based on clinical examination diagnosed the patients.  Normal subjects, 
as control, were selected from general healthy population.  The cases and controls 
included in the present study have some specific characters due to which they were 
different from general people.  Characteristics of cases and controls are given in 
Table 3. 
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3.2 CRITERIA FOR SELECTION OF ASTHMA CASES 
Patients and normal healthy controls were selected based on criteria set in the 
questionnaire filled at the sample collection time having all the required 
information. 
 
3.2.1 Criteria for Inclusion  
 
i. The Adult patient above age of 12 years and no upper age limit 
ii. No gender bias discrimination 
iii. Those individuals who show interest and sign the consent form 
iv. Patients suffering from asthma 
 
3.2.2 Criteria for Exclusion 
 
i. Individuals less than 10 years of age. 
ii. Individuals not willing to sign the informed consent form. 
iii. Patients not certainly diagnosed with asthma 
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Table 3: Characteristic of asthma patients and controls. 
 Asthma Patients Controls 
Sample size 333 521 
Mean Age (Years ± SE) 40 ± 0.93 37 ± 0.77 
Males 148 (44.5%) 316 (60.6%) 
Females 185 (55.5%) 205 (39.3%) 
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3.3 DNA EXTRACTION AND QUANTIFICATION 
 
About 4 to 5ml venous blood was drawn in Acid Citrate Dextrose (ACD) 
vaccutainers by means of sterile syringes.  Before genomic DNA extraction blood 
samples were stored at 4°C.  The blood was processed for genomic DNA isolation 
by the method of phenol chloroform extraction (Sambrook and Russel, 2001).  For 
the extraction of DNA 15 mL cell lysis buffer (155 mM Ammonium Chloride, 0.1 
mM EDTA, 10mM Potassium Bicarbonate) was added in a 50mL tube along with 
blood sample.  These samples were placed on ice for 30 minutes and were 
centrifuged at 1200 rpm for 10 minutes for complete lysis of RBCs in the samples.  
The supernatant was discarded and above procedure was repeated with fresh cell 
lysis buffer.  The WBCs pellet obtained was resuspended in 4.75 mL of STE buffer 
(100mM Sodium chloride, 50mM Tris, 1mM EDTA).  To this mixture 250µL 10% 
SDS was added dropwise to lyse the WBCs and 10µL of proteinase K (20 mg / 
mL) was added to denature the proteins.  The tubes were then incubated in water 
bath at 55 °C over night. 
 
After digesting overnight with proteinase K, in each tube equal quantity of 
Equilibrated Phenol (pH=8) Chloroform and Isoamylalcohol (24:1) mixture (1:1) 
was added.  After shaking well for 10 minutes so that a homogenous mixture is 
formed, tubes were placed on ice for ten minutes.  These tubes were then 
centrifuged for thirty minutes at 3200 rpm.  In the extracted aqueous layer 5mL ice 
43 
 
cold isopropanol along with 600µL 10M ammonium acetate was added and shaken 
well until the DNA was visible in the form of white threads. 
 
The tubes were placed at -20 °C over night.  These tubes were centrifuged at 
3200 rpm for 50 minutes.  DNA was settled down in the form of pellet.  The DNA 
pellet was washed with 5mL of ice cold 70 per cent ethanol.  The pellet was 
resuspended in 500-800 µL of 10 mM TrisHCl depending on pellet size.  The stocks 
of DNA were stored at -20 °C.  All the mentioned centrifugations were done at 4°C.   
DNA stocks were quantified by absorbance measurement at 260nm in Ultravtec 
spectrophotometer.  The 1:50 dilution of DNA (6 µL DNA in 294 µL deionized 
H2O) was prepared in a glass tube and measured the absorbance at 260nm and 
280nm respectively. 
 
Calculation of stock DNA concentration was done by using the following standard 
formula for double stranded DNA: 
Absorbance measured at 260nm × Dilution Factor (50) × Correction Factor 
(50) = DNA Concentration µg/ mL  
 
3.4 SNP SELECTION 
All genes reported for asthma were retrieved at NCBI.  From the list the genes 
strongly associated with asthma in other populations were selected.  From these 
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genes the SNPs already reported to be highly associated with asthma were searched 
using SNP flanking options present at NCBI’s (http://www.ncbi.nlm.nih.gov/) 
BLAST search engine and sequences were retrieved. 
 
3.5 GENOTYPING 
 
For genotyping, 34 SNPs in 23 different genes were selected.  Selection 
favored SNPs with evidence for association with asthma risk reported in other 
world populations and these were not studied in Pakistani population. 
 
ACE I/D polymorphism was also studied in cases and controls.  This 
rs4646994 is an insertion/deletion of an Alu repetitive element in an intron of the 
ACE gene.  Alleles having the insertion are denoted as "I" alleles and "D" alleles 
are the ones lacking this repetitive element.  Additionally, HLA class II was also 
typed in Pakistani asthmatic cases and controls.  In these DRB and DQB loci were 
typed in the cases and controls. 
 
Three different methods were used for SNP genotyping: TaqMan genotyping 
to obtain data on individual genotypes, iPLEX genotyping to analyze several SNPs 
simultaneously and one SNP with allele specific PCR.  For 28 SNPs 2 iPLEXs 
were designed; one for 20 SNPs and the other for 8 SNPs.  In iPLEX designed for 
20SNPs, 2 SNPs did not work and for those we designed TaqMan assay and rest of 
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the six SNPs were also typed by TaqMan assay.  This genotyping was done in 
Department of Human Genetics, University of Chicago, Chicago, USA. 
 
3.6 iPLEX 
 
The iPLEX genotyping by matrix-assisted laser desorption ionization-time of 
flight mass spectrometry (MALDI-TOF MS) on the MassArray platform 
(Sequenom) was used in this present study (Gabriel et al., 2009).  The SNPs 
selected for iPLEX are listed in table 4.   
This technique has the following steps. 
 
3.6.1 Multiplex PCR amplification 
 
MassArray Assay design software (ver.  3.1) was used to design the primers.  
PCR reactions were done in 384-well plates; reaction contained, in a volume of 
5µL, 60nM of the corresponding primers, 20ng genomicDNA, 1.625mM of MgCl2, 
500µM of dNTPs and 0.5U Hot Star Taq (Qiagen).  The conditions for PCR were: 
94°C for15 min, following 45 cycles of 94 °C (20 sec), 56 °C (30 sec), 72 °C (60 
sec), and finally the extension at 72 °C for 3 min.  The PCR primers list for 
amplification reaction is given in Appendix I and II. 
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After amplification to see amplification, some of the samples were separated 
on 2 per cent agarose gel before doing extension reaction (Figure 4).   
After extension reaction, it was run on Sequenom software TYPER analyzer to 
visualize all assays in the multiplex reaction.  In that the plate was visualized as 
colored traffic lights (Figure5).  These signals were shown by different SNPs and 
the mass to intensity peaks were visualized and these told about the presence or 
absence of base at that particular place (Figure 6). 
 
3.6.2 Digestion by Shrimp alkaline phosphatase (SAP reaction) 
 
Excess of deoxyribonucleotide triphosphates were dephoshorylated by adding 
0.3 USAP (iPLEX Gold Reaction Kit; Sequenom) to the PCR reaction following 
the incubation for 40 min at 37°C.  Denaturation of shrimp alkaline phosphatase 
was done at 85°C for 3 min.   
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Table 4: Single nucleotide polymorphisms done by iPLEX Technique. 
Gene Chr location rs # Allele 
(minor/major) 
IL10 1 rs1800871 T/C 
IL10 1 rs1800896 G/A 
ADRB2 5 rs1042713 A/G 
IL13 5 rs1295685 T/C 
IL13 5 rs1800925 T/C 
IL13 5 rs20541 T/C 
NOS3 7 rs1799983 T/G 
NOS3 7 rs1800779 G/A 
NPSR1 7 rs740347 C/G 
IL33 9 rs1342326 G/T 
IL18 11 rs1946518 T/G 
FCER1B 11 rs2583476 C/T 
NOS1 12 rs2682826 T/C 
IL4RA 16 rs1801275 G/A 
IL4RA 16 rs1805011 C/A 
ORMDL3 17 rs11650680 T/C 
CCL11 17 rs17809012 G/A 
CCL5 17 rs1800825 C/T 
GSDMA 17 rs3894194 T/C 
ORMDL3 17 rs8079416 T/C 
TBXA2R 19 rs1131882 A/G 
TFGB1 19 rs1800469 T/C 
TBXA2R 19 rs4523 C/T 
ADAM33 20 rs2280091 G/A 
ADAM33 20 rs528557 G/C 
ADAM33 20 rs543749 T/G 
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Figure 4: Amplification product shown on 2% agarose gel.  Gel shows just the 
amplification and here just amplification product presence is enough. 
 
 
Figure 5: The traffic lights of signals of different assays in the multiplex 
reaction. 
100 bp 
ladder 
Amplification 
product (100bp size) 
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Figure 6: In rs2583476 the peak shown at 5383.5 Daltons for C call at that 
place. 
 
 
Figure 7: The results shown after analysis by Typer analyzer showing 
rs1342326, the homozygous and heterozygous and no calls along 
with signals shown in excel file. 
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3.6.3 Extension of Primers for iPLEX 
 
MassArray design software was used to design primers for extension 
reaction.  The reaction mix for iPLEX consisted of 0.2X iPLEX buffer, 0.2 µL 
iPLEX termination mix, 0.041 µL iPLEX enzyme (iPLEX Gold Reaction Kit; 
Sequenom), and 0.056 µL to 0.113 µL primer.  The primers for extension reaction 
were divided into a high-mass group and a low mass group and the high-mass 
group concentration was doubled.  For iPLEX 2-step 200 short-cycle programs 
were used for PCR amplification.  Denaturation of the sample was done at 94 °C 
for 30 sec., annealing at 52 °C for 5 sec. and extension at 80 °C for 5 sec.  Then 
there were 4 more repetitions of annealing and extension cycles making a total of 5 
cycles, looping back to a denaturation step at 94 °C for 5 sec., and finally entered 
again to the 5-cycled loop of annealing and extension reaction.  These five 
annealing and extension steps with the single denaturing step were repeated 
additionally 39 times making a total of 40.  The final extension for 3 min. was done 
at 72 °C.  The list of extension primers is given in Appendix III and IV. 
 
3.6.4 Resin Cleaning 
 
Desaltation of iPLEX reaction products were done by adding 6 mg resin 
(Clean Resin; Sequenom) and 25 µL water to each well.  After incubation at room 
temperature for 30 min, the reaction mixture was centrifuged at 3500 g for 5min.   
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3.6.5 Data analysis and MALDI-TOF MS analysis  
 
Using a Nanodispenser the samples were dispensed onto a 384 
SpectroCHIPArray, and in MassArray Compact mass spectrometer 
SpectroCHIPArrays were introduced.  Spectra acquisition automation was 
performed using Spectroacquire (Sequenom).  The analysis of data was performed 
by using the MassArray Typer software ver.  3.4. 
 
3.7 TAQMAN 
 
TaqMan allelic discrimination assays were performed on the ABI7900HT 
Fast Real Time sequence detection system (Applied Biosystems).  The method was 
first reported in 1991 (Holland et al., 1991).  The allelic discrimination assay 
contains two different fluorescently labelled probes, one for each allele of the SNP.  
Each probe consists of an oligonucleotide with a fluorescent reporter dye at the 5’ 
end and a quencher at the 3’ end.  During PCR amplification, the TaqMan probes 
hybridize only to perfectly matching DNA, and Taq polymerase with 5’ to 3’ 
exonuclease activity cleaves the hybridized probe.  This cleavage separates the 
quencher from the reporter, allowing the fluorescence of the reporter dye to be 
detected.  The measured emission represents the genotype of each sample.  The 
PCR conditions used for amplification were 95 C for 10 min, and 40cycles of 92 C 
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for 15s and 60 C for 1 min.  The six SNPs done by TaqMan assay are listed in 
Table 5. 
 
3.8 HLA TYPING FOR HLA CLASS II ALLELES (DRB1*AND DQB1*) 
 
HLA class II alleles were screened in asthma cases and controls by means of 
sequence specific primers (PCR-SSP).   Primer mixes for HLA-DRB and DQB1 
were made according to the HLA photo typing method by Bunce et al.  (1995).  
The primer mixes, 10 xPCR buffer, and TDMH reagents were made in bulk and 
kept at -20°C for storage purpose.  All reagents were prepared in autoclaved 
deionized water.   The 10 x PCR buffer contained 670 mM Tris base pH 8.8, 66 
mM ammonium sulphate and one percent tween 20.  The TDMH consists of 
2.6xPCR buffer, 460 μM of dNTPS and 6.25 mM MgCl2.  TDMH was freshly 
prepared according to requirement and stored in 5mL falcon tubes at 4 °C. 
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Table 5: Single nucleotide polymorphisms genotyped by Taqman Technique. 
Gene Chr 
location 
rs # Literature 
cited 
Allele 
(minor/major) 
IL1R1 2 rs10173081 16 T/C 
TSLP 5 rs1837253 24,25 T/C 
TSLP 5 rs2289278 27,28 G/C 
HLA-G 6 rs1063320 9 C/G 
TLR4 9 rs4986790 33 G/A 
CC16 11 rs3741240 30,31 A/G 
ORMDL3 17 rs7216389 11 C/T 
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Figure 8: The signals of different genotypes in the TaqMan reaction showing 
homozygous, heterozygous and not amplified samples. 
 
Figure 9: The signals of different genotypes in the TaqMan reaction showing 
homozygotes and .heterozygotes and not amplified samples. 
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3.8.1 Polymerase Chain Reaction with Sequence Specific Primers for HLA 
Class II Typing 
 
Polymerase chain reaction with sequence specific primers (PCR-SSP) was 
done for each patient and control sample, using the method as given by Bunce et al.  
(1995).  PCR was done in 13 μL final volume in 96 well plates.  Class II primer 
mixes (5 μL) were aliquoted in to labeled plates using the multichannel dispenser.  
Master mixes was prepared, that included 5 μL of TDMH, 0.187 units of Taq 
polymerase, 0.1 ng of DNA sample per reaction, and then to each primer mix in the 
96 well plate, 8 μl of the master mix was added.  The plates were properly sealed 
with the sealing films.  PCR was done, using cycling conditions of one min at 96 
°C following 5 cycles of 25 sec at 96°C, 45 sec at 70 °C and 72 °C for 45 sec, then 
21 cycles of 96 °C for 25 sec, 65 °C for 50 sec and 72 °C for 45 sec, following the 
4 cycles of 25 sec at 96 °C, 55 °C for one min and 72 °C for two min and last step 
was 1 cycle for 10 min at 72 °C. 
 
3.8.2 Agarose Gel Electrophoresis 
 
The amplimers were separated on 2 per cent agarose gel, prepared in 0.5 X 
Tris-Acetate-EDTA, (TAE) buffer.  5 μL of ethidium bromide (5 μg / mL) was 
added into the gels to visualize the DNA bands under UV lights.  In each sample 
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before running on the gel, 5 μL of loading dye orange G (6 X) was added.  The gels 
were electrophoresed for about one hour at 120 volts until the dye migrated at least 
3 cm.  DNA ladder of 100bp was used as standard marker to identify alleles 
according to size.  The gels were photographed under UV light.  Positive band for 
different alleles were scored and the haplotypes were determined (Figure 10). 
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Figure 10: Agarose Gel Electrophoresis showing results of HLA typing class 
II. 
100bp 
ladder 
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3.9 ANGIOTENSIN- CONVERTING-ENZYME INSERTION/DELETION 
POLYMORPHISM 
 
Angiotensin-converting enzyme (ACE) Alu I/D polymorphism in intron 16 
were studied using primers sequences as given in Table 6.  A 15 μL volume was 
used for each PCR reaction, each reaction contained 1 μM of both primer, 1x of 
10xPCR buffer, 0.45 μM of MgCl2, 200 μM of dNTPS and 1 U of Taq DNA 
polymerase (Fermentas EU) and 30 ng of DNA as final concentration per reaction.  
PCR cycling parameters were, 1 cycle 94 °C for three min, following 35 cycles of 
94 °C for 45 sec, 58 °C for one min, and 72 °C for 45 sec and of 1 cycle of 72 °C 
for 10 min (Batzer et al., 1996). 
 
Amplicons were separated on two percent agarose gels and after staining with 
ethidum bromide agarose, gels were visualized under UV transilluminator.  The 
fragment D allele is at the size of 190 bp while the I allele is seen at the size of 490 
bp.  Both size bands were present in ID heterozygotes.  DNA ladder of 100 bp was 
used as standard (Figure 11). 
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3.10 TUMOR NECROSIS FACTOR ALPHA 308 POLYMORPHISM 
 
Tumor Necrosis Factor (TNF) alpha 308 was typed using PCR-SSP by using 
primers sequences as given in Table 7.  The sequence specific primers of TNF 
alpha 308 consisting of one forward and two reverse primers were used.  In this β-
Globin was used as positive controls.  A 15 μL volume was used for each PCR 
reaction, each reaction contained 1 μM of both primer, 1x of 10xPCR buffer, 0.45 
μM of MgCl2, 200 μM of dNTPS and 1 U of Taq polymerase ( Fermentas EU ) and 
30 ng of DNA as final concentration per reaction.  PCR cycling parameters were, 
one cycle at 95 °C for 5 min, following 31 cycles at 95 °C for 90 sec, 61 °C for 150 
s, at 72 °C for one min and of one cycle for 10 min at 72 °C. 
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Table 6: Primer sequences of ACE I/D polymorphism. 
Forward 5' – CTGGAGACCACTCCCATCCTTTCT-3' 
Reverse 5'-GATGTGGCCATCACATTCGTCAGAT-3'  
 
 
 
 
Table 7: Primer sequences of TNF alpha 308 polymorphism. 
TNF-144/-164 5'-TCTCGGTTTCTTCTCCATCG-3' 
TNF-A1-328/-308G 5'-ATAGGTTTTGAGGGGCATGG-3' 
TNF-A2-320/-308A 5'-ATAGGTTTTGAGGGGCATGA-3' 
BETA-GLOBIN(A) 5'-ACACAACTGTGTTCACTAGC-3' 
BETA-GLOBIN(B) 5'-CAACTTCATCCACGTTCACC-3' 
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Figure 11: Agarose Gel Electrophoresis showing results of ACE I/D PCR 
products. 
100bp ladder 
490bp 
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200bp 
500bp 
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The amplimers were separated by using two percent agarose gel 
electrophoresis and after staining with ethidum bromide agarose gels were 
visualized under UV transilluminator.  The fragment of size 185 bp represented 
TNF alpha 308 G/A polymorphism while a fragment of 110 bp represented the 
positive control of beta Globin.  DNA ladder of 100 bp was used as standard in the 
gel (Figure 12). 
 
3.11 STATISTICAL ANALYSIS 
 
Phenotype characteristics are described as the means ± standard error (SE).   
 
Association testing 
 
Association of individual genetic variants and asthma was calculated using logistic 
regression, adjusted for age, and sex, assuming an additive genetic model.  The 
results are presented in the form of odds ratio (OR) along with 95 per cent 
confidence intervals (CI). 
 
The analysis of variance was calculated by Statistical Package for Social 
Sciences (SPSS) for significant variation between class II allelic frequencies and 
haplotypes two locus in the asthma cases and controls (Voelki and Gerber, 1999).  
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For a particular locus where only one allele was found that sample was said to be 
homozygous.  Calculations for odd ratio (OR) and 95 per cent confidence interval 
(CI) were done by means of calculator for Odds Ratios (http:// 
www.hutchon.net/ConfidOR.htm; Bland and Altman, 2000).  The OR significance 
was calculated by using the 2 x 2 chi-square contingency- test with Yates' 
correction for continuity (http://faculty.vassar.edu/lowry/ VassarStats.html).  
Hardy-Weinberg equilibrium (HWE) was calculated by Arlequin Version 3.0 
software (http://cmpg.unibe.ch/software/ arlequin3; Schneider et al., 2000)  
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Figure 12: Agarose Gel Electrophoresis showing results of TNF α 308 PCR 
products. 
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Comparison of the case and control groups was done by Fisher Exact test.  In 
case of ACE I/D polymorphism and TNF alpha 308 polymorphism the OR with 
95% CI were calculated by means of the online statistical software package for 2-
way Contingency table analysis (http://vassarstats.net/odds2x2.html). 
 
3.12 META-ANALYSIS 
 
Electronic databases like Med line and PubMed were searched up to February 
2014 for all genetic studies involving HLA DRB1*0701 and HLA DQB1*06 
typing in asthma in humans in different studies all around the world.  Studies 
selected in our meta-analysis were all done on human beings, they were case 
control based studies, data for detailed genotypes frequency of patients and controls 
were available.  Meta-analysis was done using Comprehensive Meta-analysis 
version 2 Biostat, Englewood, NJ, 2004.  The association of HLA DRB1*0701 and 
HLA DQB1*06 with asthma was estimated for each study by OR and 95 per cent 
CI. 
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Chapter 4 
RESULTS AND DISCUSSION 
 
In present study, 854 blood samples were collected from asthma patients and 
healthy individuals.  Samples were genotyped for different associated genes SNPs 
in cases and controls.  The case-control specific gender distributions are provided in 
(Table 3).  Mean age of our population was 40 + 0.93 in cases and 37 + 0.77 in 
controls.   
 
4.1 GENOTYPE/ALLELEFREQUENCIES AND HARDY-WEINBERG 
EQUILIBRIUM IN CASES AND CONTROLS 
 
In the present study, total 34 different SNPs of different genes were analyzed 
by using three different techniques; iPLEX, Taqman, and sequence specific PCR.  
The results of these SNPs are shown in Table 8.  The allele and genotype 
frequencies of all the samples including cases and controls were analyzed for 
Hardy-Weinberg equilibrium (HWE).  The genotype distributions for all SNPs 
were consistent with HWE except for rs740347 (NPSR1) and rs1946518 (IL18) 
having values HW_P= 0.000701 and 0.007414 respectively (Table 8).  These two 
SNPs were therefore excluded from the study and remaining 32 SNPs were 
included for further analysis. 
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The allele and genotype frequencies of all SNPs were also separately 
calculated for the cases and controls as shown in tables 9 and 10.   The HWE 
values for SNPs rs1946518 (IL18), rs740347 (NPSR1) and rs2280091 (ADAM33) 
showing deviation from HWE (p=0.02) were excluded from study controls.  In 
asthma cases, two SNPs, rs1342326 (IL33) and rs740347 (NPSR1) deviated from 
HWE (p=0.04) and thus were not included in the final analyses.   
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Table 8: SNPs with their call rates, minor allele frequency and Hardy-
Weinberg Equilibrium p-values. 
S. No Gene SNP Call Rate 
Minor Allele 
Frequency 
(MAF) 
HWE p-value 
1 IL1R1 rs10173081 0.99 0.06 0.99 
2 TLR4 rs4986790 1.00 0.11 0.22 
3 IL10 rs1800871 0.97 0.40 0.23 
4 IL10 rs1800896 0.97 0.26 0.22 
5 IL13 rs1295685 0.97 0.31 0.15 
6 IL13 rs1800925 0.96 0.22 0.38 
7 IL13 rs20541 0.96 0.30 0.05 
8 IL18 rs1946518* 0.95 0.34 0.01 
9 IL33 rs1342326 0.97 0.17 0.09 
10 IL4RA rs1801275 0.97 0.20 0.25 
11 IL4RA rs1805011 0.97 0.05 0.05 
12 TSLP rs1837253 0.99 0.32 0.56 
13 TSLP rs2289278 0.92 0.09 0.35 
14 TGF-β1 rs1800469 0.96 0.35 0.05 
15 CC16 rs3741240 0.98 0.40 0.62 
16 CCL5 rs1800825 0.97 0.03 0.43 
17 CCL11 rs17809012 0.96 0.45 0.62 
18 ADRB2 rs1042713 0.96 0.43 0.57 
19 NPSR1 rs740347* 0.96 0.08 0.00 
20 FCER1B rs2583476 0.97 0.48 0.19 
21 GSDMA rs3894194 0.96 0.49 0.77 
22 NOS1 rs2682826 0.97 0.29 0.33 
23 NOS3 rs1799983 0.97 0.19 0.65 
24 NOS3 rs1800779 0.96 0.20 0.23 
25 HLA-G rs1063320 0.96 0.26 0.09 
26 ORMDL3 rs11650680 0.97 0.22 0.60 
27 ORMDL3 rs8079416 0.96 0.49 0.78 
28 ORMDL3 rs7216389 0.90 0.41 0.20 
29 TBXA2R rs4523 0.96 0.48 0.38 
30 TBXA2R rs1131882 0.96 0.19 0.25 
31 ADAM33 rs2280091 0.94 0.19 0.06 
32 ADAM33 rs528557 0.91 0.39 0.16 
33 ADAM33 rs543749 0.94 0.19 0.33 
 
 
*The SNPs that are not in Hardy-Weinberg equilibrium. 
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4.2 ASSOCIATION OF GENOTYPES AND ALLELES WITH ASTHMA 
4.2.1 Association of SNPs in Interleukin Genes 
 
In interleukins different genes were selected.  One SNP each of IL1R1, TLR4, 
and IL33 gene, two SNPs in IL10 and IL4RA and three SNPs of IL13 were 
genotyped in cases and controls For IL1R1gene, one SNP rs10173081 was studied 
in a case control model.  As mentioned in table 11, it was found that no allele was 
associated with asthma significantly (p=0.14).  Similarly forTLR4, one SNP 
rs4986790 was typed in 337 patients and 169 controls and no significant 
association with asthma was observed (p=0.63).  The IL-1 family has been 
involved in inflammatory and immunologic responses (Dinarello, 2009).  Members 
contain activators and suppressors of inflammation.  Interleukin-1 receptors (IL-
1Rs) and Toll-like receptors (TLRs) are members of a large superfamily of 
phylogenetically conserved proteins involved in innate immunity and inflammation 
(Mantovani et al., 2007).  The common characteristics of these two receptor 
families include their presence in the cytoplasmic region of a conserved sequence 
called Toll/IL-1R (TIR) domain (Dinarello, 2009; O'Neill, 2008).  The IL-1R/TLR-
driven immune response also has an essential role in the induction and/or 
regulation of allergic inflammation and disease exacerbations. 
 
For IL10, two SNPs, rs1800871 and rs1800896were typed.  For rs1800871, 
324 patients and 176 controls and for rs1800896, 326 patients and 172 controls 
were included.  The rs1800871 has no significant association with asthma in 
Pakistani population (p=0.11).  In rs1800896 minor allele G had significant 
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association with risk of asthma in our studied Pakistani population (p=0.04).  The 
G allele carriers are at increased odds of disease as compared to non-carriers 
(OR=1.38, 95% CI=1.01-1.88)). 
 
IL-10 is known to be important in immuno-regulation and is considered as an 
immune-suppressive factor (Lyon et al., 2004; Guzowski et al., 2005; Rees et al., 
2002).  Low levels of IL-10 expression have a role on the pathogenesis of asthma 
(Makela et al., 2000; Tarzi et al., 2006).  On the other hand, high level of IL-10 
from regulatory T cells has a protective effect against airway hyper-reactivity and 
inflammation (Stampfli et al., 1999).  The polymorphism rs1800896 conferred 
susceptibility to asthma in East Asians and adult asthmatics.  It lies within a 
putative ETS-like transcription factor binding site, it has been reported that G 
position may be associated with a higher expression of the IL-10 gene (Mormann et 
al., 2004; Gruber et al., 2008).  The association with the G allele in the Pakistani 
population is consistent with results of studies in Indian (Chatterjee et al., 2005), 
Egyptian (Hussein et al., 2011) and studies from other regions (Chung, 2001; 
Asadullah et al., 2003; Barnes, 2002).  A few studies have also reported the 
opposite allele as in Korean population the association is with A allele (Park et al., 
2004).   
 
For IL13, three SNPs rs1295685, rs1800925 and rs20541 were analyzed.  
Among these only rs1800925 SNPs minor T allele has shown significant 
association towards disease (p=0.03) increasing disease risk (OR=1.45 with 95% 
CI=1.04-2.02) in allele carriers.  For the other two SNPs rs1295685 (p=0.68) and 
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rs20541 (p=0.81) there was no association in our study population.  Interleukin (IL-
13) is a critical mediator in the pathogenesis of allergic inflammation (Hershey, 
2003).  This cytokine up-regulates major histocompatibility complex class II 
expression and promotes IgE isotype switching.  This cytokine is found to be 
critical to the pathogenesis of allergen-induced asthma but operates through 
mechanisms independent of IgE (Leonardo et al., 2008).  It has also been reported 
that the rs1800925 (-1112C/T) polymorphism resulted in enhanced promoter 
activity (Vladich et al., 2005).  In spite of the importance of IL-13 in asthma (Karp 
et al.,1998; Noakes et al., 2003; Feleszko et al., 2006) some studies failed to show 
an association between IL13 polymorphisms and asthma phenotypes (Leung et al., 
2001; Hakonarson and Wjst,2001), possibly because of different prevalence of 
environmental risk factors such as tobacco smoke exposure.  Beghé (Beghé et al., 
2010) reported associations of rs1800925, rs1295685 and rs20541 in IL13 with 
both atopy and asthma.  These are different SNPs which are located in IL13 and all 
are not in LD with each other.  In the present study these three SNPs were 
genotyped in Pakistani cases and controls however only rs1800925 showed 
significant disease association.  In all above mentioned studies, including ours, the 
T allele is associated with disease susceptibility. 
 
In IL33, SNP rs1342326 was typed in 325 patients and 175 controls and no 
significant association of this SNP was observed with asthma (p=0.64).  IL-33 
induces the expression of IL-4, IL-5, and IL-13 and leads to severe pathologic 
changes in mucosal organs (Schmitz et al., 2005).  Mice injected with human IL-33 
exhibit impressive pathologic changes in the arterial walls, lungs, and intestinal 
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tissues (Schmitz et al., 2005).  Of particular relevance to the concept of IL-33-
driven Th2 response is the prominent eosinophilic infiltration in lung tissue.  
Airway smooth muscle cells have IL-33 expression in both the protein and mRNA 
levels.  IL-33 expression increases in bronchial biopsies in asthmatic subjects 
compared to controls, as well as subjects with severe asthma (Préfontaine et al., 
2009). 
 
In IL4RA two SNPs, rs1801275 (328 patients and 172 controls) and 
rs1805011 (322 patients and 176 controls) were typed.  Both SNPs lacked 
significance in association towards disease in our studied Pakistani samples with p 
values=0.64 and 0.21 respectively. 
 
4.2.2 Association of SNPs in Other Cytokines 
 
Two SNPs, rs1837253 and rs2289278 of TSLP gene were typed in 327/307 
patients and 185/167 controls respectively.  Both SNPs lacked association (p=0.23 
and 0.92 respectively) with asthma risk in our population.  For TFGB1 gene, 
rs1800469 SNP was genotyped in 324 patient and 170 controls.  This SNP also 
lacked association towards disease (p=0.54). 
 
Transforming growth factor-β1 (TGF-β1) is a multifunctional cytokine that 
may influence asthma by modulating allergic airway inflammation and airway 
remodeling (Duvernelle et al., 2003).  It is important in growth, transformation, 
tissue repair, fibrosis and the modulation of immune inflammatory responses 
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(Blobe et al., 2000).  Its levels in bronchoalveolar lavage (BAL) fluid are higher in 
asthma patients and increase further in response to allergen exposure compared 
with healthy control subjects (Redington et al., 1997).  Several SNPs in this 
cytokine have been studied for association with asthma and atopy, including 
rs1800469.  This SNP in the TGF-β1promoter appears to influence TGF-β1 blood 
levels (Grainger et al., 1999; Suthanthiran et al., 2000) and gene expression in the 
lung (Silverman et al., 2004).  Association of this and other TGF-β1 SNPs with 
wheezing illness in infants (Hoffjan et al., 2004), asthma diagnosis (Mak et al., 
2006; Silverman et al., 2004), severity (Pulleyn et al., 2001) and increased IgE in 
asthmatic children (Hobbs et al., 1998) have been found in some studies (Buckova 
et al., 2001; Heinzmann et al., 2005).  In the present study no association between 
rs1800469 in TGF-β1and asthma samples was reported.  The T allele at this SNP 
has been associated with asthma or related phenotypes in many previous studies 
(Celedón et al., 2004; Nagpal et al., 2005; Li et al., 2007).   
 
4.2.3 Association of SNPs in Chemokines 
 
For CC16 gene, one SNP rs3741240 was typed in 326 patients and 179 
controls.  This marker lacked significant association with asthma in our study 
population (p=0.61).  Similarly, rs1800825 SNP of CCL5 and rs17809012 SNP of 
CCL11 were genotyped for their association with asthma.  None of the SNPs 
showed significant association with disease having p values 0.53 and 0.39 
respectively. 
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4.2.4 Association of ADRB2, FCER1B, GSDMA Genes SNPs with Asthma  
 
Three SNPs, rs1042713, rs2583476, rs3894194 from ADRB2, FCER1B and 
GSDMA, genes each were also genotyped in present study.  None of the SNPs 
showed significant association towards asthma with p values 1.0, 0.09 and 0.65 
respectively.   
 
4.2.5 Association of SNPs in NOS1, NOS3, HLA-G Genes 
 
Three SNPs, rs2682826 NOS1 and rs1799983 and rs1800779 from NOS3 
genes were also genotyped in our asthma cases and healthy controls.  No 
significant association (p=0.60, 0.36 and 0.67 respectively) of asthma with these 
SNPs was observed in our study population.  Similar results were obtained for 
rs1063320 SNP of HLA-G gene (p=0.39).   
 
4.2.6 Association of SNPs in Genes ORMDL3, TBXA2R 
 
For ORMDL3 gene, three SNPs rs11650680, rs8079416 and rs7216389 were 
typed.  In all three SNPs no significant result was obtained having p values=0.54, 
0.46 and 0.47 respectively (Table 11).  For TBXA2R gene, two SNPs rs1131882 
and rs4523 were genotyped in 325 patients and 171 controls.  The minor allele of 
rs1131882 (TBXA2R) showed significant association (p=0.05) with disease (Table 
11).  However, an OR of 0.73 (95% CI=0.52-1.01) seems to indicate some 
protective role of this SNP in our population.   In order to fully explore exact role 
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of this SNPs as disease marker (risk/protective), large scale studies need to be 
conducted.  The second TBXA2R SNP rs4523, we did not find any significant 
association with disease (p=0.71).   
 
The thromboxane A2 receptor (TBXA2R) is a potent broncho- and 
vasoconstrictor and is associated with leukotriene synthesis.  It is involved in 
prostaglandin and leukotriene pathways, and has diverse physiological and 
pathophysiological actions related to allergies, modulation of acquired immunity, 
atherogenesis, and neovascularization (Nakahata, 2008).  Polymorphisms in the 
TBXA2R gene have been associated with urticarial (Palikhe et al., 2011).  This 
study investigated associations between asthma- and TBXA2R polymorphism.  We 
have found a borderline association between rs1131882 (TBXA2R) and asthma in 
Pakistani population.  Its significance is at borderline.  It shows here that A allele is 
associated with protection in Pakistani population.  In Japanese population genetic 
variants in the TBXA2R gene were also associated with asthma-related phenotypes 
(Takeuchi et al., 2013).  Thromboxane pathways may therefore play important 
roles in airway inflammation and remodeling in asthma patients. 
 
4.2.7 Association of SNPs in ADAM33 Gene 
 
In ADAM33 gene, three SNPs rs2280091, rs528557 and rs543749 were 
studied for disease association.  For rs528557, 300 patients and 167 controls were 
typed while for rs543749, 318 patients and 167 controls were typed.  In both these 
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SNPs no significant associations were observed having p=1.0 and 0.31 
respectively. 
 
The rs2280091 (ADAM33) has significant p value of 0.03 with reference to 
minor allelic condition as shown in table 11.  Its significance is also shown in the 
odds ratio value and 95 per cent confidence interval (OR = 0.69; 95% CI = 0.50-
0.97).  In this study 318 patients and 169 controls were genotyped.  The first strong 
genetic evidence suggests that genes in non-allergic, non-immune pathways may 
play important roles in asthma pathogenesis was the report of ADAM33 as the first 
positionally cloned asthma gene (Eerdewegh et al., 2002; Ober and Yao, 2011).  
ADAM33 encodes a disintegrin and metalloprotein-33 protein that participates in 
the bronchial remodeling process in asthma (Vergaraa et al., 2010).  Asthma is a 
complex disease, but learning more about how SNP mutations in ADAM33 give 
rise to asthmatic conditions will provide important clues in treating asthma.  The 
ADAM33 gene has been found to be expressed in lung fibroblasts, and bronchial 
smooth muscle, but not in bronchial epithelial cells.  This indicates a strong link 
between the ADAM33 gene and asthmatic conditions.  Strong association of 
rs2280091 (ADAM33) in Taiwanese (Chiang et al., 2012) and Saudi population 
was reported (Al-Khayyat et al., 2012).  It was also reported to be associated with 
Asian population (Liang et al., 2013).  In the present study we have also found a 
very strong association of this polymorphism showing association of G with 
protection which is in contrast to above mentioned study.  This difference may be 
due to different genetic makeup of our population.   
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From the SNPs based studies it was concluded that variations in TBXA2R, 
ADAM33, IL10 and IL13 genes seem to offer disease protection in the Pakistani 
population.  Further studies will be needed to replicate these associations in the 
Pakistani population and to elucidate the mechanism for these observations. 
 
4.3 GENDER BASED ASSOCIATION BETWEEN SNPs AND ASTHMA 
 
All age and gender adjusted genotyped data was also explored for gender 
based disease association. 
 
4.3.1 SNP Genotypes Distribution in Male Subjects 
 
For all genotyped SNPs no gender specific disease association was seen 
except FCER1B gene.  For FCER1B gene SNP, rs2583476 has shown significant 
genotype distribution in males.  As shown in table12, the asthmatic male gender 
had higher TT genotype counts as compared to controls.  The homozygous TT and 
CC genotype frequencies in cases were; TT 35 per cent and GG 24.3 per cent as 
compared with controls; CC 24 per cent and GG 27.7per cent.  These results clearly 
indicate that in our sample population of male gender TT genotype is highly 
prevalent in asthma patients as compared to healthy controls, whereas, GG 
genotype is not much different between males in cases and controls.  Gender 
specific association with this SNP in asthma patients has not been reported in 
different world populations.   
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4.3.2 SNP Genotypes Distribution in Female Subjects 
 
In female gender, the only significant association found was in ORMDL3 
gene SNP rs11650680.  As shown in table 12, heterozygous CT genotype is more 
prevalent in female asthma cases as compared to controls female population.  In 
case control data, the CT genotype frequency in female cases is 36 per cent and 23 
per cent in control female subjects.  These results clearly show that CT genotype of 
ORMDL3 gene SNP rs11650680 is highly prevalent in female asthma cases as 
compared to healthy controls in our study population.    
 
4.3.3 Gender Based Comparison of SNP Genotypes among Asthma Cases and 
controls 
 
A comparison was also made between male and female subjects with regards 
to genotype frequencies of studied SNPs under case-control model (Table 12).  For 
FCER1B gene SNP rs2583476 significant difference existed in genotype 
frequencies among male and female cases (OR=1.86, 95% CI=1.09-3.17, p=0.01).  
The odds ratio results clearly indicate that male subjects are at higher risk of asthma 
as compared to female counter-parts.  Genotype frequencies also depicted high 
prevalence of risk allele in males as compared to females.   In case of ORMDL3 
gene SNP rs11650680, our results indicate that female asthma subjects carriers of 
CT genotype are at higher risk of disease as compared to male asthmatic subjects 
(OR=1.99, 95% CI=1.02-3.89, p=0.03).   
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4.4 ASSOCIATION OF SNPs WITH AGE IN ASTHMA 
 
Concerning age, our study population was distributed among three age groups: 
< 18 years, 18-40 years and >40 years.  Genotype frequencies in each group are 
listed in Table 13.  Of all 31 SNPs genotyped in our population, only one SNP 
rs1800896 (IL10) showed significant association with age (p=0.0067).  Based on 
rs1800896 (IL10) genotype analysis, 18-40 years age group is at the highest risk of 
disease (OR=10.69, 95% CI=4.74-24.12) as compared to >40 years of age.  There is 
a considerable difference in the cases and controls with as shown in table 13.   
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Table 9: Allele and genotype frequencies in controls and the Hardy-Weinberg p-values. 
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Table 10: Allele and genotype frequencies in cases and the Hardy-Weinberg p-values. 
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Table 11: Allele and genotype frequencies in cases and controls and Odds Ratio with p values. 
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Table 12: Genotype distribution among male and female gender in cases and controls and Odds Ratio with p values. 
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Table 13: Genotype distributions among different age groups in asthma cases and controls. 
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4.5 GENOTYPING FOR TNF- Α -308 G/A POLYMORPHISM 
The genotype distribution of TNF- α -308 G/A polymorphism were not in 
HWE within each group that is cases or controls.  The genotypes and alleles 
frequencies of TNF- α -308 G/A polymorphism in asthma cases and control 
subjects are shown in Table 14 and 15.  We did not find any significant difference 
in the prevalence of this polymorphism between cases and control subjects of 
studied Pakistani population.   
 
TNF- α is a potential candidate gene among many genes involved in the 
induction of airway inflammation.  Given the biological regulation of TNF-α and 
its role in the inflammatory process, it is perhaps surprising that the genetic 
influences on cytokine production have much influence on disease processes and 
their outcome.  The associations between TNF-α genotype and disease are not 
absolute as suggested by different conflicting studies (Witte et al., 2002; Randolph 
et al., 2005).  Nevertheless, it is clear that the genetic regulation of TNF-α at sites 
of inflammation is important.  Under circumstances where the release of TNF-α has 
triggered the genetically endowed capacity for greater TNF-α production leads to 
more severe inflammatory reactions. 
 
Previous studies have shown an association between the TNF- α -308 G/A 
polymorphism and asthma (Gupta et al., 2005; Louis et al., 2000).  In present study 
lack of TNF- α -308 G/A polymorphism association with asthma suggests that -308 
G/A allele could not be considered as a genetic factor for susceptibility to asthma in 
our studied population.  These results can be re-analyzed by increasing number of 
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cases and controls and the results in future studies and its role as a disease marker 
could be confirmed. 
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Table 14: Genotypes, χ2 and Odds Ratio (OR) of TNF α-308 in asthma cases  
and controls. 
Asthma patients Controls OR 
Genotype 
n=329 n=151 
χ
2
 
(95% CI) 
p-
value 
1.049 
GG 88(27%) 39(26%) 0.05 
(0.68-1.63) 
0.823 
0.987 
GA 241(73%) 111(73%) 0 
(0.64-1.53) 
1 
-- 
AA 0(0%) 1 (0.006%) -- 
(--) 
-- 
 
 
 
Table 15: Alleles, χ2 and Odds Ratio (OR) of cases (Asthma) and controls for 
TNF alpha-308. 
Alleles Asthma Cases controls OR 
 n=329 n=151 
χ2 
(95% CI) 
p-value 
G 417 189 0.06 
1.03 
(0.78-1.37) 
0.806 
A 241 113 0.06 
0.967 
(0.73-1.28) 
0.806 
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4.6 GENOTYPING FOR ACE I/DPOLYMORPHISM 
 
The genotype distribution of ACE I/D polymorphism were in HWE within 
each group of cases or controls.  The frequency of genotypes and alleles of ACEI/D 
in the asthma cases and controls are presented in Table 16 and 17.  This marker has 
shown strong association with disease in our population (p≤0.0001).Our 
genotyping results indicate that homozygous insertion (II) significantly increased 
the risk of asthma (OR=3.38, 95% CI=2.35-4.84) as compared to deletion which 
The heterozygous insertion/deletion (ID) seemed to have a protective role with 
regards to asthma susceptibility (OR=0.43, 95%CI=0.33-0.57 and p≤0.0001).   
 
Followed by genotypes, ACE I/D alleles were also analyzed separately in 
cases and controls and checked for their association with asthma in studied 
Pakistani population.  As presented in Table 17, these results have shown that I 
allele is strongly associated with asthma risk in studied population (OR=1.4, 95% 
CI=1.15-1.7, p=0.0007) whereas deletion allele is showing association towards 
asthma protection (OR=0.71, 95% CI=0.59-0.87, p=0.0007).   
 
The insertion/deletion (I/D) polymorphisms of ACE gene have also been 
implicated in susceptibility to asthma as it affects serum ACE levels, but many 
earlier studies have reported inconclusive results.  Angiotensin converting enzyme 
DD genotype has been reported as more prevalent in asthmatics (Benessiano et al., 
1997; Gao et al., 2000) and has also stated that ACE DD genotype is related with 
severe disease presentation (Eryuksel et al., 2009; Gao et al., 2000).  However, 
others did not find association between ACE I/D genotypes and asthma or asthma 
severity (Chagani et al., 1999; Lee et al., 2000; Nakahama et al., 1999).  
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Table 16: Genotype frequencies, χ2 and Odds Ratio (OR) of ACE I/D 
polymorphism in asthma cases and controls.  
 
Asthma 
patients 
Controls OR (95% CI) Genotype 
n=333 n=521  
p-value 
 
II 99(30%) 58 (11%) 46.83 3.38 (2.35-4.84) 
 
<0.0001 
 
ID 140 (42%) 326(63%) 34.54 0.43 (0.33-0.57) <0.0001 
 
DD 94(28%) 137(26%) 0.38 1.11 (0.81-1.5) 0.54 
  
 
Table 17: Allele frequencies, χ2 and Odds Ratio (OR) of ACEI/D in asthma 
cases and controls. 
 
Alleles Asthma Cases controls OR 
 n=333 n=521 
χ2 
(95% CI) 
p-value 
I 338(51%) 442(42%) 11.37 1.40 
(1.15-1.70) 
0.0007 
D 328(49%) 600(58%) 11.37 0.71 
(0.59-0.87) 
0.0007 
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A recent meta-analysis has suggested that I/D polymorphism of the ACE 
gene would be a risk factor for asthma (Zhang et al., 2011).  Results of this meta-
analysis indicated that DD homozygote carriers had almost 59 per cent increased 
risk of asthma and this risk is more evident in Asians, especially in children.  In 
contrast, a study conducted on adult Turkish population (Yildiz et al., 2004; Urhan 
et al., 2005) reported that ACE gene I/D polymorphisms are not an important 
determinant of asthma susceptibility.  Our study is the first from Pakistan exploring 
relationship between ACE I/D genotype and asthma risk.   
 
Different results from the literature about ACE I/D polymorphisms may be 
explained by the genetic heterogeneity and multifactorial etiology of asthma.  
Multicentre studies with a large number of patients are required to confirm these 
results.  In the present study, it was concluded that homozygous II gene 
polymorphism is a risk factor for asthma in studied Pakistani population. 
 
4.7 HLA TYPING OF CLASS II ALLELES IN ASTHMA 
 
Twenty-five HLA class II alleles were tested in relation to asthma incidence 
using available subjects for each allele results are summarized in tables 18 and 19.  
Of these 25 alleles, 14 alleles were of HLA Class II locus DRB1 and 11 of locus 
DQB1.   Of DRB1 locus, HLA DRB1*0701 allele was significantly associated 
(p=0.01) towards an increased risk of asthma (OR=1.586; 95% CI=1.150-2.186).  
Several studies on diverse world populations have reported association of 
DRB1*07 with asthma/disease.  A study on 109 patients of allergy in United 
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Kingdom has shown that DRB1*07 is seen to be associated with increased risk of 
asthma (Jeal et al., 2003).  In another study on venome, sensitive cases has reported 
DRB1*07 association with allergy (Faux et al., 1997).  While in a study on Iranian 
cases of pulmonary disease, DRB1*07 was reported to be positively associated 
with increased risk of disease (Amirzargar et al., 2004).  All these studies are in 
parallel with ours showing DRB1*07 as a strong disease marker.  In comparison 
one study on Slovak population reported lack of association of DRB1*07 with 
disease (Dzurilla et al., 2013).  The difference may be due to different genetic 
makeup and different environmental agents responsible for asthma in studies 
showing disease association with DRB1*07. 
 
The DQB1* allele results are shown in table19.  Out of the 11 alleles of the 
DQB1* locusDQB1*03032 allele was associated with an increased risk of asthma 
in our studied Pakistani population (OR=2.42; 95% CI=1.34-4.35; p=0.02).  While 
two alleles; DQB1*06 and DQB1*0602 showed trend towards protection from 
asthma (Table 9).  According to our findings DQB1*06 allele carriers (OR=0.39; 
95%CI=0.22-0.70; p≤0.0001) and DQB1*0602 allele carriers (OR=0.27; 
95%CI= 0.10-0.71; p≤0.0001) significantly decrease the risk of disease.   In 
contrast to our findings, a study of 311 Caucasian Canadian allergy patients and 
226 controls reported DBB1*06 allele to be associated with disease susceptibility 
(Madore et al., 2013).  In another study on 109 asthma patients of Slovak 
population, it was seen that DQB1*03 and DQB1*06 lack association with disease 
(Dzurilla et al., 2013).   
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The other 21 HLA class II alleles of interest lacked significance in association 
with asthma incidence in our population.  In present study, we have found that the 
frequency of the HLA class II alleles DQB1*03032 was significantly high among 
asthma patients as compared to ethnically matched healthy control subjects while 
the frequency of DQB1*06 and DQB1*0602 significantly decreased. 
 
4.7.1 Haplotype Analysis Of HLA Class II 
 
The two locus haplotype for the HLA loci DRB1 and DQB1 are made by 
Arlequin.  In this, 115 haplotypes were seen in cases and 128 haplotypes were 
observed in controls.  In these 34 haplotypes have frequencies of more than 2 per 
cent in each group and these > 2 % haplotypes are shown in table20. 
 
In the table 20 it is shown that some of the haplotypes such as DRB1*01-
DQB1*05, DRB1*11-DQB1*0601, DRB1*12-DQB1*0301/0304, DRB1*13-
DQB1*06, DRB1*1302-DQB1*06, DRB1*15-DQB1*06 have shown significant p 
values but in the analysis their OR and 95% CI did not coincide with those p 
values.  Therefore, these were showing wrong associations.  When we look at the 
haplotype frequencies in both cases and controls it was also confirmed that there 
was not much difference between both subjects.  The haplotypes DRB1*13-
DQB1*02, DRB1*15-DQB1*05 and DRB1*15-DQB1*0603 have shown 
significant p values but the LD is negative so here it is not taken into consideration 
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as they are not in LD.  Therefore, these haplotypes are not showing the right 
significance. 
 
The haplotypes DRB1*0701-DQB1*06, DRB1*14-DQB1*05 and DRB1*15-
DQB1*0602 were present only in controls and not found in cases and these 
haplotype were seen to be significantly associated with protection in the Pakistani 
population.  DRB1*0701-DQB1*03032was the haplotype that is present in both 
cases and controls with significant p value with OR and 95% CI.  All these have 
shown its association with protection in Pakistani population.  These all haplotypes 
were following the linkage disequilibrium (LD) and is significantly associated with 
asthma protection in Pakistani population (Table20). 
 
120 
 
Table 18: DRB1* alleles frequencies, F test, Odds Ratio (OR) and p values in cases and controls. 
DRB Alleles Freq in Cases Freq in Controls F test P P corrected OR (95% CI) 
DRB1*01 0.03 0.04 0.66 0.42 5.84 0.79 (0.45-1.39) 
DRB1*03 0.19 0.20 0.06 0.80 11.24 0.97 (0.74-1.26) 
DRB1*04/1122 0.07 0.07 0.07 0.79 11.06 1.06 (0.70-1.59) 
DRB1*0701 0.15 0.10 8.06 0.01 0.07 1.59 (1.15-2.19) 
DRB1*08 0.13 0.01 0.31 0.58 8.11 1.32 (0.49-3.54) 
DRB1*09 0.02 0.01 1.21 0.27 3.82 1.57 (0.69-3.53) 
DRB1*1001 0.05 0.04 1.89 0.17 2.38 1.43 (0.86-2.38) 
DRB1*11 0.08 0.10 1.95 0.16 2.28 0.77 (0.53-1.11) 
DRB1*12 0.01 0.02 0.08 0.77 10.84 0.88 (0.36-2.16) 
DRB1*13 0.08 0.08 0.10 0.75 10.47 0.94 (0.64-1.38) 
DRB1*1302 0.02 0.02 0.32 0.58 8.05 1.23 (0.59-2.58) 
DRB1*14 0.04 0.05 3.06 0.08 1.12 0.63 (0.37-1.06) 
DRB1*15 0.22 0.24 0.51 0.48 6.68 0.91 (0.71-1.17) 
DRB1*16 0.01 0.02 0.08 0.77 10.84 0.88 (0.36-2.16) 
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Table 19: DQB1* alleles frequencies, F test, Odds Ratio (OR) and p values in cases and controls. 
DQB Alleles Freq in Cases Freq in Controls F test P P corrected OR (95% CI) 
DQB1*02 0.26 0.26 0.00 0.96 10.51 1.01 (0.79-1.28) 
DQB1*0301/0304 0.14 0.12 0.28 0.60 6.53 1.09 (0.79-1.49) 
DQB1*0302 0.04 0.03 1.65 0.20 2.19 1.45 (0.82-2.54) 
DQB1*03032 0.05 0.02 9.22 0.00 0.02 2.42 (1.34-4.35) 
DQB1*0305 0.01 0.00 1.23 0.27 2.95 2.21 (0.53-9.26) 
DQB1*04 0.02 0.01 3.26 0.07 0.78 2.44 (0.90-6.64) 
DQB1*05 0.20 0.21 0.01 0.91 9.98 0.98 (0.76-1.28) 
DQB1*06 0.03 0.06 10.73 0.00 0.01 0.39 (0.22-0.70) 
DQB1*0601 0.15 0.14 0.16 0.69 7.56 1.06 (0.79-1.43) 
DQB1*0602 0.01 0.03 8.15 0.00 0.04 0.27 (0.10-0.71) 
DQB1*0603 0.91 0.11 0.95 0.33 3.62 0.84 (0.59-1.20) 
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Table 20: DQB1* alleles frequencies, F test, Odds Ratio (OR) and p values in cases and controls. 
 
 
continued 
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HF (Haplotype frequency), LD (linkage Disequilibrium), ANOVA (Analysis of Variance) 
 
Table 20  Page 4 
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4.7.2 META-ANALYSIS OF HLA DRB1*0701 AND HLA DQB1*06 TYPING 
AND ASTHMA 
 
The results of HLA DRB1*0701 and HLA DQB1*06 meta-analysis are given 
in Table21 and 22 and interpretation by forest plot is shown in Figure 13 and14.  
Meta-analysis was done using data of HLA DRB1*0701 typing of 5 studies of UK, 
American, Irani, Slovak and Pakistani population (594 patients and 1070 controls) 
and HLA DQB1*06 typing based on 3 studies of Caucasians, Slovak and Pakistani 
population (723 patients and 768 controls).  In forest plots each square represents 
the OR point estimate and its size is proportional to the weight of the study.  The 
diamond shape represents the overall summary estimate, with confidence interval 
given by its width. 
 
A significant association (p=0.00) between the HLA-DRB1*07 and asthma 
was observed in over all analysis with an OR of 1.607 (95%CI of 1.299-1.987) in 
considering Fixed Model while in random model this significance was retained 
(p=0.001) with an OR of 1.633 (95%CI of 1.212-2.202).  The Meta analysis of 
DRB1*07 including our study proves the authenticity of DRB1*07 our significance 
results in comparison with other world populations (Jeal et al., 2003; Faux et al., 
1997; Amirzargar et al., 2004).  According to forest plot the study on different 
populations favors our study (Figure 14).  The present study was showing the same 
trend of association of DRB1*07 with risk of asthma as in other world populations 
considered as shown in figure 14. 
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In case of HLA-DQB1*06 no significant associations was found in combined 
analysis in either of the models (Table 22).  The forest plot of the study has also 
shown contradictory results (Figure 13).  For Meta analysis of HLA DQB1*06 we 
did not find enough studies where this allele is reported for association with 
asthma.  Only two populations (Caucasians and Slovak) were found having 
DQB1*06 association with asthma.  Therefore, due to less number of studies the 
significance of association might have been lost.  However, we did find association 
in our population in the present study and it is possible that this association is 
population specific as many studies have shown population specific associations.  
For example, in a previous study on HCV in Pakistani population there was an 
association of disease with DRB1*07 and DQB1*02 (Ali et al., 2010).  In another 
study on Pakistani population rheumatic heart disease was reported to be associated 
with DRB1*07 (Rehman et al., 2007).  Therefore, it is possible to observe 
population specific associations as well as those shown by some previous studies 
(Ali et al., 2010; Rehman et al., 2007).  The present association of asthma with 
DQB1*06 can help clinicians for further management of the disease.   
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Table 21: Meta-analysis of case-control studies of HLA DRB1*07. 
 
Model 
Total 
Studies 
OR (95%CI) 
 
Z-value p-value 
 5    
Fixed  1.607(1.299-1.987) 4.378 0.000 
Random  1.633(1.212-2.202) 3.219 0.001 
  
 
Table 22: Meta-analysis of case-control studies of DQB1*06. 
 
Model 
Total 
Studies 
OR (95%CI) 
 
Z-value p-value 
 3    
Fixed  0.925(0.68-1.26) -0.492 0.623 
Random  
0.997(0.368-
2.699) 
-0.006 0.995 
  
 
.
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Model HLA-DQB06 Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
This study 0.397 0.224 0.704 -3.162 0.002
Anne-Marie et al., 2013 2.820 1.470 5.411 3.118 0.002
Dzurilla et al., 2013 0.918 0.590 1.429 -0.379 0.705
Fixed 0.925 0.680 1.260 -0.492 0.623
Random 0.997 0.368 2.699 -0.006 0.995
0.01 0.1 1 10 100
Favours A Favours B
Meta Analysis
 
Figure 13: Forest plot of the DQB1*06 and asthma in over all analysis. 
130 
 
Model HLA-DRB07 Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
This study 1.586 1.150 2.187 2.815 0.005
Hayley Jeal et al 2003 1.820 1.118 2.964 2.407 0.016
Faux et al 1997 2.100 1.196 3.687 2.583 0.010
Amirzargar et al 2004 2.700 1.190 6.128 2.375 0.018
Dzurilla et al 2013 0.925 0.548 1.561 -0.293 0.770
Fixed 1.607 1.299 1.987 4.378 0.000
Random 1.633 1.212 2.202 3.219 0.001
0.01 0.1 1 10 100
Favours A Favours B
Meta Analysis
 
Figure 14: Forest plot of the DRB1*07 and asthma in over all analysis. 
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SUMMARY 
 
Asthma is a chronic inflammatory disorder of lungs and airways.  It is 
characterized by specific symptoms for example bronchial arrest, narrowing of 
airways, wheezing and cough.  In spite of the development the affected individuals 
number is increasing day by day all around the world.  About 300 million people 
worldwide and almost 20 million people in Pakistan are the victims.  During 
asthmatic attack special types of cells such as eosinophils and Th2 cells accumulate 
in airways that narrow the airways and patient feel difficulty in breathing.   
Asthma is an interactive disease and is caused by combination of 
environmental and genetic factors.  A number of genes are found to be associated 
with asthma in different studies.  Many single nucleotide polymorphisms (SNPs) 
are found in these genes and their association with different diseases has been 
established.  Many of the SNPs of ADAM33, IL10, IL13 and TBXA2R are found to 
be associated with asthma and other respiratory disorders and their association is 
confirmed by genome wide association studies and linkage analysis in different 
population.  But Genetic screening of Pakistani population for association between 
these and some other reported genetic variants and asthma has yet not been 
established.  Therefore the proposed study was designed to screen the local 
population to check the association under following objectives:  
The purpose of the present study is the genetic analysis of asthmatic Pakistani 
population and study of candidate genes and polymorphisms associated with 
asthma in Pakistani population.  For this purpose
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854 samples of healthy and asthma patients were genotyped by using Sequence 
specific PCR, iPLEX and Taqman assay.  HLA class II was typed by using sequence 
specific PCR.  For SNP analysis 34 SNPs of 28 different genes were genotyped and 
ACE I/D polymorphism was also genotyped.  To check the association of SNPs with 
asthma with specific gender and age groups statistical analysis was performed.  These 
results clearly shows that there is a strong association between asthma susceptibility, 
and IL10(rs1800896) and IL13 (1800925) minor alleles; however, an association with 
protection was found between ADAM33(rs2280091) and asthma in Pakistani study 
population.  For FCER1B gene, rs2583476 has shown a significant genotype 
distribution in males.  In our sample population of male gender TT genotype is highly 
prevalent in asthma cases as compared to healthy controls.  In ORMDL3 rs11650680 
has shown the significant genotype distribution in females.  In our sample population 
of female gender CT genotype is highly prevalent in asthma cases as compared to 
healthy controls.  In rs1800896 (IL10) significant association has been shown in age 
group 18-40 years and more than 40 years of age.  For ACE I/D polymorphism the II 
genotype is a risk factor for asthma in Pakistani population.   
HLA DRB1*0701 and HLA DQB1*03032 was significantly associated with an 
increased risk of asthma in current study.  DQB1*06 and DQB1*0602 were reported 
to be associated with protection of asthma in present study population.  The haplotypes 
DRB1*0701-DQB1*06, DRB1*14-DQB1*05, DRB1*0701-DQB1*03032 and 
DRB1*15-DQB1*0602 were seen to be significantly associated with protection in the 
Pakistani population. 
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APPENDICES 
 
Appendix I 
Table 1: List of 20 SNPs done by iPLEX and their amplification primers 
sequence with amplicon lengths 
SNP_ID Amplification Primer sequence Amplicon Length (bp) 
rs1800896 ACGTTGGATGGACAACACTACTAAGGCTTC 94 
rs1295685 ACGTTGGATGAATGAGTGTGTTTGTCACCG 100 
rs1801275 ACGTTGGATGACCCTGCTCCACCGCATGTA 108 
rs1042713 ACGTTGGATGAGCGCCTTCTTGCTGGCA 97 
rs1799983 ACGTTGGATGACCTCAAGGACCAGCTCGG 96 
rs1800925 ACGTTGGATGGGGTTTCTGGAGGACTTCTA 80 
rs1131882 ACGTTGGATGTCATGGCAGGCGGGTTTCG 85 
rs543749 ACGTTGGATGTGCCACACAGCTTGCAGCC 84 
rs2280091 ACGTTGGATGCTGTCCAGTGGCTGTGGG 97 
rs2289278 ACGTTGGATGTAGGCGGCAAAGTTTACGAG 100 
rs1800825 ACGTTGGATGGCATTGGCCGGTATCATAAG 100 
rs1800469 ACGTTGGATGAGGGTGTCAGTGGGAGGAG 100 
rs11650680 ACGTTGGATGAAAAGACTGTCAGAGAAGGC 98 
rs1946518 ACGTTGGATGTGCTGTATCAGATGCAAGCC 100 
rs8079416 ACGTTGGATGTGTCTGGATCACTCTGTTGG 100 
rs3894194 ACGTTGGATGAAGTCGATGAGGCTGTCAAG 100 
rs3771180 ACGTTGGATGGATTTGTGGCCAAATCTATG 91 
rs2682826 ACGTTGGATGGCCATGTTCCAGTGGTTTCA 93 
rs740347 ACGTTGGATGATTCACCCTTCCACAACAGC 89 
rs17809012 ACGTTGGATGGCAAGAAAACCAAGGCCCTA 99 
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Appendix II 
Table 2: List of 8 SNPs done by iPLEX and their amplification primers sequence with amplicon lengths 
SNP_ID Amplification Primer sequence Amplicon Length (bp) 
rs2583476 ACGTTGGATGGAACAATTACTGATGTTCAAC 93 
rs1805011 ACGTTGGATGAGGAACAGGCTCTCTGTTAG 90 
rs1800779 ACGTTGGATGACCAGATGCCCAGCTAGTG 89 
rs1342326 ACGTTGGATGGAAGTATTTGGAGTCCAAAAG 93 
rs1800871 ACGTTGGATGGACCCCTACCGTCTCTATTT 95 
rs528557 ACGTTGGATGAGTCGGTAGCAACACCAGG 100 
rs4523 ACGTTGGATGCTGGAACCAGATCCTGGAC 97 
rs20541 ACGTTGGATGTGATGCTTTCGAAGTTTCAG 100 
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Table 3: List of 8 SNPs done by iPLEX and their extension primers sequence with their calls and masses 
SNP_ID 
EXT1_Seq 
E2 
Cal
l 
E2 
Mass EXT2_Seq 
rs258347
6 CCATGCGCCTTTATGTAC T 
5463.
4 CCATGCGCCTTTATGTAT 
rs180501
1 CTTCCAGGAGGGAAGGGC A 
5571.
7 CTTCCAGGAGGGAAGGGA 
rs180077
9 GGGGTTTGTAGTTCTGTGC T 
5878.
8 GGGGTTTGTAGTTCTGTGA 
rs134232
6 TTTTCTCATGAAGACACCAG T 
6073.
9 TTTTCTCATGAAGACACCAT 
rs180087
1 CCCTTGTACAGGTGATGTAAC T 
6459.
1 CCCTTGTACAGGTGATGTAAT 
rs528557 CCTGCTGCCTCTGCTCCCAGGC C 
6597.
3 CCTGCTGCCTCTGCTCCCAGGG 
rs4523 CACGGCGCGGCGGAACAGGATA C 
6793.
4 CACGGCGCGGCGGAACAGGATG 
rs20541 
AAAGAAACTTTTTCGCGAGGGAC
C T 
7367.
8 AAAGAAACTTTTTCGCGAGGGACA 
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Appendix III 
Table 4: List of 20 SNPs done by iPLEX and their extension primers sequence with their calls and masses 
SNP_ID 
EXT1_Seq 
E2 
Call 
E2 
Mass EXT2_Seq 
rs1800896 CCTATCCCTACTTCCCCC A 5304.3 CCTATCCCTACTTCCCCT 
rs1295685 CCCTTGGCTCCAAGTGCC T 5449.4 CCCTTGGCTCCAAGTGCT 
rs1801275 tCCCCACCAGTGGCTATCA G 5682.7 tCCCCACCAGTGGCTATCG 
rs1042713 GGTCCGGCGCATGGCTTCC A 5834.7 GGTCCGGCGCATGGCTTCT 
rs1799983 caCTGCAGGCCCCAGATGAG T 6109.9 caCTGCAGGCCCCAGATGAT 
rs1800925 tCTTTTCCTGCTCTTCCCTCA C 6199 tCTTTTCCTGCTCTTCCCTCG 
rs1131882 TCCCCTTTGCAGGTCTTCATC A 6337 TCCCCTTTGCAGGTCTTCATT 
rs543749 GAGGATATGTTGTCCCCTAAG T 6459.1 GAGGATATGTTGTCCCCTAAT 
rs2280091 ttccGGGCGGCGTTCACCCCAC A 6686.2 ttccGGGCGGCGTTCACCCCAT 
rs2289278* CTCCCCTTTCACTCAATTCTCAC G 6803.5 CTCCCCTTTCACTCAATTCTCAG 
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rs1800825 CCGGAGGCTATTTCAGTTTTCTC T 7034.5 CCGGAGGCTATTTCAGTTTTCTT 
rs1800469 gattCCTCCTGACCCTTCCATCCC T 7173.5 gattCCTCCTGACCCTTCCATCCT 
rs11650680 aaaAAAACCAGCTCAAAATTCTCC T 7304.7 aaaAAAACCAGCTCAAAATTCTCT 
rs1946518 TGCAGAAAGTGTAAAAATTATTAC T 7389.9 TGCAGAAAGTGTAAAAATTATTAA 
rs8079416 aattGTTTTCCTGCCACCAATACAC T 7573.8 aattGTTTTCCTGCCACCAATACAT 
rs3894194 cCCCTGGCCAGACAGCTAAACCCTCA C 7804.1 cCCCTGGCCAGACAGCTAAACCCTCG 
rs3771180 ACATCAAGAATTCTTAGTACATGATG A 7975.1 ACATCAAGAATTCTTAGTACATGATT 
rs2682826 cccCTCTTGCCGACAAGGGCAACTCAC T 8188.2 cccCTCTTGCCGACAAGGGCAACTCAT 
rs740347 gcatGGTTGTTCAGATTATTTATGCTC C 8284.4 gcatGGTTGTTCAGATTATTTATGCTG 
rs17809012 gacgTTGGTTTCCTTGCTCCTTTCCCCC A 8406.5 gacgTTGGTTTCCTTGCTCCTTTCCCCA 
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